Introduction {#sec1}
============

The nonselective cation channel TRPM2 (transient receptor potential cation channel, subfamily M, member 2) is activated in a Ca^2+^-dependent manner after binding of the nucleotide ADP-ribose (ADPR) to its cytosolic C-terminal NUDT9*H* domain that shares homology with a mitochondrial nucleotide pyrophosphatase NUDT9.^[@ref1]^ While earlier studies indicated that the NUDT9*H* domain also has a low pyrophosphatase activity, hydrolyzing ADPR to AMP and ribose 5-phosphate (R5P),^[@ref2]^ a recent study showed that the Nudix box motif in TRPM2 does not support catalysis and the production of AMP might have been due to spontaneous hydrolysis of ADPR at alkaline pH.^[@ref3]^

Reactive oxygen species (ROS) and genotoxic stress can result in release of ADPR from the nucleus due to the activation of the poly(ADP-ribose) polymerase-1 (PARP-1) and poly(ADP-ribose) glycohydrolase pathways.^[@ref4],[@ref5]^ The ADPR so generated can then activate TRPM2, resulting in prolonged Ca^2+^-entry, mitochondrial Ca^2+^-overload, and apoptosis,^[@ref6]^ thereby contributing to cell damage in post ischemic reperfusion injury during myocardial infarction^[@ref7]^ and stroke.^[@ref8]^

Besides this role in cell death, TRPM2 also participates in physiological processes like inflammation.^[@ref9]^ In neutrophil granulocytes and dendritic cells, TRPM2 contributes to chemotaxis.^[@ref10]−[@ref12]^ The chemotaxis of murine neutrophils in response to fMLP is independent of PARP-1 but can be inhibited by 8-Br-ADPR, a compound that inhibits activation of TRPM2 by ADPR, and by knock-out of CD38, a glycohydrolase that produces ADPR from NAD.^[@ref10]^ In macrophages and monocytes, TRPM2 is involved in secretion of chemokines and cytokines in response to ROS and pro-inflammatory cytokines,^[@ref13],[@ref14]^ whereas in effector T cells, it plays a role in proliferation and secretion of pro-inflammatory cytokines.^[@ref15]^ Inhibition of TRPM2 has been shown to reduce tissue damage after stroke by preventing invasion of neutrophils,^[@ref16]^ and knock-out of TRPM2 ameliorates the symptoms of experimentally induced autoimmune encephalomyelitis, a model for multiple sclerosis.^[@ref15]^ TRPM2 is thus an attractive pharmacological target for the treatment of neurodegenerative and autoimmune diseases.^[@ref17],[@ref18]^

Further investigations into the role of TRPM2 in physiology and pathophysiology require specific modulators of channel function, and their rational design will benefit from a better understanding of its structure--activity relationship (SAR). Recently, TRPM2 structures from three different species were elucidated by cryo-EM. The structure of RPM2 from the sea anemone *Nematostella vectensis* nvTRPM2 lacks the NUDT9*H* domain, probably because of the flexibility of this part of the molecule.^[@ref19]^ TRPM2 from zebrafish (*Danio rerio*) drTRPM2 has been solved in the apo state and in an ADPR-bound state.^[@ref20]^ While ADPR could not be localized in the NUDT9*H* domain, electron density corresponding to ADPR was found in the *N*-terminal MHR1/2 domain. Comparison of the conformations of the apo and the ADPR-bound state and mutational analysis indicate that in drTRPM2, gating of the channel occurs via binding of ADPR to the MHR1/2 domain instead of NUDT9*H*.^[@ref20]^ Structures of human TRPM2 (hTRPM2) have been resolved for the apo state, an ADPR bound (primed) state and an open conformation bound to ADPR and Ca^2+^.^[@ref21]^ Mutagenesis of the MHR1/2 domain and removal of the NUDT9*H* domain show that in the human TRPM2 channel, gating occurs after binding of ADPR to the NUDT9*H* domain, but again poor resolution prevents the placement of ADPR in the presumed binding pocket. Structure-based drug design therefore still awaits a high-resolution structure of either the full-length channel or the isolated NUDT9*H* domain of TRPM2.

Recently, we synthesized ADPR analogues to explore the role of the adenosine, pyrophosphate, and terminal ribose motifs in activation of TRPM2.^[@ref22],[@ref23]^ The pyrophosphate-forming couplings used employed morpholidate- or CDI-mediated methodologies. Yields were generally low and reaction times were generally long and improvements are warranted. To our surprise, the majority of structural modifications of ADPR led to compounds that do not activate TRPM2, indicating that all three moieties are required for channel opening.^[@ref23]^ These studies also revealed that hydroxyl group removal at C2′ resulted, in the case of ADPR, in a compound that is a TRPM2 agonist with significantly higher efficacy than ADPR itself^[@ref23]^ and also improved the antagonist 8-Ph-ADPR (IC~50~ 11 μmol/L compared to 8-Ph-2′-deoxy-ADPR, IC~50~ 3 μmol/L).^[@ref22]^ We also highlighted the importance of the terminal ribose for TRPM2 activation by evaluating a series of modified ADPR analogues.^[@ref29]^ While simple ADP neither activated nor antagonized the channel, introduction of substituents at the β-phosphate that increasingly resembled the terminal ribose ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) returned antagonist properties, but none of the analogues exhibited agonist activity. The fact that β-(tetrahydrofuran-2-yl)methyl-ADP, an analogue with the ribofuranose backbone, but lacking the hydroxyl groups, did not activate the channel but instead antagonized TRPM2 indicated that one or more of the hydroxyl groups might be important for the gating of TRPM2. Previous studies have shown hydroxyl group deletion to be a valuable tool in SAR elucidation for complex bioactive molecules.^[@ref24]−[@ref26]^ While such endeavors may be synthetically protracted in order to effect a desired precision edit to the parent molecule, they can divulge key mechanistic information.^[@ref27],[@ref28]^

![Structure of ADPR and known terminal ribose analogues.^[@ref29]^](jo-2019-00338t_0001){#fig1}

We report here the synthesis and electrophysiological evaluation of novel terminal-ribose-modified analogues of the TRPM2 agonists ADPR and 2′-deoxy-ADPR to study the role of the individual hydroxyl groups of the terminal ribose in TRPM2 activation. The critical step of analogue formation was achieved by combining a sugar phosphate with a P-activated nucleotide to form a single molecule linked by a pyrophosphate bond. A recently reported improved procedure for the preparation of NDP sugars from nucleoside phosphorimidazolides^[@ref36]^ uses 2--4 equiv of magnesium chloride to achieve high reaction yields and short reactions times for nucleoside 5-phosphorimidazolide coupling to sugar phosphates.

Results and Discussion {#sec2}
======================

The terminal ribose of ADPR is essential for the ligand-driven activation of the cation channel TRPM2.^[@ref29]^ To investigate the SAR of this part of ADPR in more detail, we focused upon the synthesis of all three possible 1″-deoxy, 2″-deoxy, and 3″-deoxy terminal ribose ADPR derivatives **2**, **3**, and **4** by selective deletion of the appropriate hydroxyl group ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The similar reactivity of the ribose hydroxyl groups and potential for ring opening of the cyclic hemi-acetal required development of multistep synthetic routes with selective masking and deprotection. The modified ribose building blocks were then coupled to either AMP or 2′-deoxy-AMP via pyrophosphate coupling reaction ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). We also synthesized a corresponding analogue **1** with all hydroxyl groups present, but blocked with small alkyl groups to interrogate the H-bond donating capability of the terminal ribose ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The chemically stable analogues were evaluated regarding their agonist and antagonist activity by patch-clamp experiments in whole cell configuration using HEK cells with stable expression of human TRPM2.

![Pyrophosphate coupling reaction and ADPR analogues prepared in this study.](jo-2019-00338t_0002){#fig2}

At first, routes to the required modified terminal ribose 5-phosphates were designed. It was envisaged that such phosphates would be ideal coupling partners for activated nucleotide imidazolides. Protected ribose monophosphate **9** was chosen to exploit the ligand space around the terminal ribose, H-bond donating capability, and its good susceptibility for coupling with activated nucleosides. The precursor of **9**, compound **8**, was obtained from protected ribose^[@ref30]^**7** by phosphitylation with dibenzyl *N*,*N*-diisopropylphosphoramidite and subsequent oxidation using hydrogen peroxide^[@ref31]^ to afford **8** (79%) ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A). Compound **8** was then hydrogenated using Pd/C to afford **9** (82%). Ribose-5-monophosphate **9** was converted to its tributylammonium salt and freeze-dried. Synthesis of 1-deoxyribose-5-phosphate **10**, to explore the role of the anomeric OH group of the terminal ribose, started from 2,3-*O*-isopropylidene ribose **13** that was protected at position 5 by a trityl group, to afford **14** (65%) ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B). Reduction of **14** by sodium borohydride led to compound **15** (85%). Reaction of **15** with tosyl chloride in pyridine gave no significant result at room temperature, but heating the reaction mixture up to 60 °C helped to afford the protected 1-deoxyribose **16** (80%). However, deprotection of **16** with acetic acid failed after multiple attempts, as both the 5-*O*-trityl and 2,3-*O*-isopropylidene protecting groups were cleaved, leading to the undesired fully deprotected 1-deoxyribose or to complex mixtures. Using the alternative deprotection of **16** with formic acid in diethylether^[@ref32]^ afforded compound **17** (32%).^[@ref33]^ Phosphitylation and subsequent oxidation of **17** with di-*tert*-butyl *N*,*N*-diisopropylphosphoramidite gave the phosphate derivative **18** (41%). Careful deprotection of **18** with aqueous trifluoroacetic acid at low temperature afforded the target 1-deoxyribose-5-phosphate **10** (49%) that was subsequently converted to its tributylammonium salt.

![Synthesis of Modified Terminal Riboses **9** and **10**\
Reagents and conditions: (a) 5-Ph-1-*H*-tetrazole, dibenzyl *N*,*N*-diisopropylphosphoramidite, DCM, 20 °C, 1 h; (b) triethylamine, H~2~O~2~, 0--20 °C, 1 h; (c) hydrogen (balloon), Pd/C, 5 h, TEAB (1 M), 20 °C; (d) Dowex D50 (H^+^), tributylamine; (e) tritylchloride, pyridine, 20 °C, 16 h; (f) sodium borohydride, ethanol, 0--20 °C, 2 h; (g) tosyl chloride, pyridine, 60 °C, 16 h; (h) HCOOH/diethylether, 20 °C, 16 h; (i) 5-Ph-1-*H*-tetrazole, di-*tert*-butyl *N*,*N*-diisopropylphosphoramidite, DCM, 20 °C, 1 h; (j) triethylamine, H~2~O~2~, 0--20 °C, 1 h; (k) aqueous TFA, 0--20 °C, 4 h; (l) Dowex D50 (H^+^), tributylamine.](jo-2019-00338t_0005){#sch1}

Synthesis of the 2-deoxy version of the terminal ribose ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}) started from commercially available 2-deoxyribose-5-phosphate sodium salt **19** (Sigma-Aldrich) that was converted to its corresponding mono-tributylammonium salt **11** by using Dowex resin (H^+^ form) followed by titration with tributylamine to pH ≈ 7 ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}A). Partial decomposition (20--30%) of **19** was observed during the transformation to **11** via ^31^P NMR, suggesting that 2-deoxyribose-5-monophosphate is less stable toward changes in pH (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.9b00338/suppl_file/jo9b00338_si_001.pdf), S14--16) compared to its 1-deoxy- and 3-deoxy-counterparts. Synthesis of 3-deoxyribose-5-monophosphate **12** started from 1,2-*O*-isopropylidene xylose **20**,^[@ref34]^ which was protected at the 5-hydroxyl group as the TBDPS ether to give **21** (83%) ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}B). Reaction of **21** with 1,1′-thiocarbonyldiimidazole in DCM afforded compound **22** (63%). Reductive deoxygenation of **22** with tributyltin hydride led to the compound **23** (76%) which was subsequently deprotected in buffered TBAF to give 1,2-*O*-isopropylidene-3-deoxyribose **24** (82%). Phosphitylation and subsequent oxidation of **24** gave the desired di-*tert*-butyl phosphate derivative **25** (50%). However, several attempts to deprotect compound **25** with aqueous TFA led to a complex mixture, suggesting that di-*tert*-butyl protected phosphate **25** was not the optimal precursor for **12**. Therefore, **24** was phosphitylated and subsequently oxidized to its dibenzylphosphate derivative **26** (72%) that was successfully deprotected to give **27** (68%). Hydrogenation of **27** followed by neutralization of the free phosphate using tributylamine afforded the target analogue 3-deoxyribose-5-phosphate as its mono-tributylammonium salt **12** (67%).

![Synthesis of Modified Terminal Riboses **11** and **12**\
Reagents and conditions: (a) Dowex D50 (H^+^), tributylamine; (b) TBDPS chloride, DMAP, pyridine, 20 °C, 16 h; (c) 1,1′-thiocarbonyldiimidazole, DCM, reflux, 2 h; (d) tributyltinhydride, AIBN, toluene, 116 °C, 3 h; (e) TBAF·3H~2~O, acetic acid, 20 °C, 3 h; (f) 5-Ph-1-*H*-tetrazole, di-*tert*-butyl *N*,*N*-diisopropylphosphoramidite, DCM, 20 °C, 1 h; (g) triethylamine, H~2~O~2~, 0--20 °C, 1 h; (h) various conditions with aqueous TFA; (i) 5-Ph-1-*H*-tetrazole, dibenzyl *N*,*N*-diisopropylphosphoramidite, DCM, 20 °C, 1 h; (j) triethylamine, H~2~O~2~, 0--20 °C, 1 h; (k) aqueous TFA, 0 °C, 1.5 h; (l) hydrogen (balloon), Pd/C, 4 h, 20 °C; (m) tributylamine.](jo-2019-00338t_0006){#sch2}

In previous work, we used morpholidate chemistry or 1,1′-carbonyldiimidazole-based methodology in coupling reactions, but these had been less than satisfactory during ADPR analogue preparation. To find the most suitable conditions here for pyrophosphate bond formation between the corresponding ribose-5-monophosphate and either AMP or 2′-dAMP, two different methods were tried. Activation of AMP tributylammonium salt with 1,1′-carbonyldiimidazole^[@ref35]^ followed by addition of the triethylammonium salt of ribose **9** did show formation of the desired pyrophosphate product **1** by high-performance liquid chromatography (HPLC). However, several byproducts were also observed (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.9b00338/suppl_file/jo9b00338_si_001.pdf) Figure S1a, S2). In contrast, following the Dabrowski-Tumanski procedure^[@ref36]^ activation of the AMP tributylammonium salt using imidazole, 2,2′-dithiodipyridine (Aldrithiol) and triphenyl phosphine cleanly afforded the AMP-imidazolide that was isolated by precipitation with a cold solution of NaI in acetone. When stirred with the triethylammonium salt of **9** and magnesium chloride in dimethylformamide (DMF), the AMP-imidazolide gave almost exclusively the desired compound **1** (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.9b00338/suppl_file/jo9b00338_si_001.pdf) Figure 1b, S2--S3). Finally, purified target ribose derivatives **9**, **10**, **11**, and **12** were individually coupled to imidazolide-activated AMP or 2′-deoxy-AMP ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Adenosine-5′-monophosphate **28** and 2′-deoxy-adenosine-5′-monophosphate **29** were transformed to their imidazolides **30** and **31**, by reaction of the corresponding mono-tributylammonium salt of **28** and **29** and imidazole using the Aldrithiol and triphenylphosphine condensation protocol.^[@ref36]^ Imidazolides **30** and **31** were precipitated from the reaction mixture by addition of a 0.1 M solution of sodium iodide in cold, anhydrous acetone and were directly used for coupling. The target modified ADPR analogues **1**--**6** were then prepared by coupling^[@ref36]^ the corresponding imidazolide **30** or **31** and mono-tributylammonium salt of the modified ribose-5-phosphate **9**, **10**, **11**, or **12** to give variable yields of the desired ADPR analogues **1** (24%), **2** (66%), **3** (8%), **4** (17%), **5** (42%), and **6** (27%). Final compounds **1--6** were purified by semi-preparative HPLC using triethylammonium bicarbonate (TEAB) buffer and isolated as the corresponding triethylammonium salts.

![Synthesis of Target Terminal-Modified ADPR Analogues\
Reagents and conditions: (a) Aldrithiol, imidazole, triethylamine, triphenylphosphine, 20 °C, 16 h; (b) NaI, acetone (precipitation), 0 °C; (c) MgCl~2~, dimethylformamide, 20 °C, 3--16 h.](jo-2019-00338t_0007){#sch3}

Stability of Terminal-Modified ADPR Analogues **1--6** {#sec2.1}
------------------------------------------------------

The stability of ADPR analogues **1**--**6** was evaluated using analytical HPLC. Aqueous solutions of **1**--**6** stored at 5 °C were compared with freshly prepared standard solutions of **1**--**6** (from solid samples stored at −20 °C). All compounds except **3** were stable in aqueous solution for several days when stored in the fridge (5 °C). Compound **3**, 2″-deoxy-ADPR, was found to be unstable under these conditions. We also observed decomposition of **3** during transport and sample preparation, so we could not do electrophysiological experiments with **3** ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.9b00338/suppl_file/jo9b00338_si_001.pdf) Figure 2, S4). The instability of **3** may correspond with the lower stability of 2-deoxyribose-5-monophosphate **11** that was sensitive toward changes in pH during conversion of the commercially available sodium salt to the tributylammonium salt (conversion of **19** to **11**). This decomposition led to hydrolysis of the 5′-phosphate (approx. 20--30% de-phosphorylation of **11** was observed via ^31^P NMR). The corresponding decomposition by de-phosphorylation in 2″-deoxy-ADPR **3** might cleave the pyrophosphate bond and would be predicted to lead to inactive fragments.

Evaluation of Novel Analogues Against TRPM2 {#sec2.2}
-------------------------------------------

Recently, we investigated the importance of the ADPR terminal ribose for the activation of TRPM2.^[@ref29]^ This can be investigated by whole cell patch-clamp experiments. During these experiments, a glass pipette with a diameter much smaller than a cell and filled with a solution mimicking the ionic composition of the cytosol is attached to the plasma membrane. By applying suction to the pipette, the membrane patch underneath the pipette is ruptured. In voltage-clamp experiments, a voltage is applied between an electrode in the pipette solution and a bath electrode in the bath solution surrounding the cells. This voltage results in ions moving through channels in the membrane resulting in a current that can be recorded.^[@ref37],[@ref38]^ In HEK293 cells expressing TRPM2, addition of ADPR to the pipette solution results in a current that is absent in wild type HEK293 cells. ADPR analogues can be tested for their ability to activate the channel, and they can also be tested for antagonist activity by adding them in addition to ADPR. We found that adenosine 5′-monophosphate (AMP) and adenosine 5′-diphosphate (ADP) neither activated or inhibited the channel even when applied in large excess over ADPR.^[@ref29]^ Interestingly, replacement of the terminal ribose of ADPR with small substituents led to analogues that did not activate the channel, but inhibited activation by ADPR, indicating that they compete with ADPR for the ligand binding site of TRPM2. Thus, activation of TRPM2 may be attributed to specific interactions between the hydroxyl groups of the terminal ribose of ADPR and the ligand binding NUDT9*H* domain of TRPM2. We evaluated the deoxy analogues **2** and **4** and an ADPR analogue **1** where all hydroxyl groups of the terminal ribose are masked and could no longer act as hydrogen bond donors ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). It was not possible to evaluate **3** biologically because of instability issues (see above and [SI](http://pubs.acs.org/doi/suppl/10.1021/acs.joc.9b00338/suppl_file/jo9b00338_si_001.pdf)). During the experiments, we included 8-Br-ADPR as a control. 8-Br-ADPR has previously been shown to inhibit activation of TRPM2 by ADPR most likely by competing with the agonist.^[@ref10]^

![Effect of ADPR analogues on whole cell currents in TRPM2 expressing HEK293 cells. Conditions: (a) Effect of ADPR analogues on whole cell currents in TRPM2 expressing HEK293 cells. Experiments were done as outlined in the [Experimental Section](#sec4){ref-type="other"}. ADPR or the indicated ADPR analogue was added to the pipette solution at a concentration of 100 μmol/L. (b) Effect of ADPR analogues on TRPM2 whole cell currents elicited by ADPR. In this case, the pipette solution contained either no nucleotide (buffer), 100 μM ADPR or a combination of 100 μM ADPR with 900 μM of the indicated ADPR analogue. 8-Br-ADPR was included as the inhibitor control. Points indicate the maximum current from individual cells. The number of cells for each condition is indicated at the bottom. Bars represent the mean of the log-transformed currents (ns = non-significant, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001). Control conditions on both panels include overlapping sets of data because on some days, both agonist and antagonist experiments were performed.](jo-2019-00338t_0003){#fig3}

As expected, the masked analogue 1″-β-*O*-Me-2″,3″-*O*-*i*Pr-ADPR **1** did not activate TRPM2 on its own ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a). Because it is more space-filling than ADPR, we were unsure whether it would compete with ADPR for binding to the NUDT9*H* domain. When applied in excess over ADPR, however, it indeed inhibited activation of TRPM2 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b), showing that further steric constraints than those simply at the 1″-position of the terminal ribose are tolerated and may potentially be exploitable for TRPM2 antagonist optimization.

Interestingly, an analogue **32** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}) of the low-affinity partial TRPM2 agonist α-β-methylene ADPR (AMPCPR)^[@ref39]^ masked in the same way as **1** was recently described to be a high affinity TRPM2 antagonist that inhibits ADPR-elicited TRPM2 currents with an IC~50~ of 5.7 μM.^[@ref40]^ Luo et al. here did not explicitly mention whether they tested this compound for TRPM2 activation but, because it fully inhibits the channel at 100 μM, it is unlikely to exhibit agonist activity. Methylene analogues may show increased stability toward cellular pyrophosphatases like NUDT9 and NUDT5 which may be retained in the cell during whole cell patch-clamp experiments. Earlier reports that indicated an ADPR pyrophosphatase activity of the NUDT9*H* domain of TRPM2,^[@ref1]^ that might contribute to degradation of agonists with pyrophosphate bridge have recently been disputed.^[@ref3]^ The observed difference could also result from different experimental conditions as we buffered the intracellular Ca^2+^ concentration to 200 nmol/L with 10 mmol/L of EGTA, whereas Luo et al. left the Ca^2+^ concentration largely unbuffered (50 μmol/L EGTA) which would result in a much steeper dependence of the current on the agonist concentration and a more pronounced inhibition by the antagonist.

![Structures of masked ADPR **1**, α-β-methylene ADPR (AMPCR) **32**, 2″-*O*-acetyl-ADPR **33**, and 3″-*O*-acetyl-ADPR **34**.](jo-2019-00338t_0004){#fig4}

Contrary to our expectations, both ADPR analogues **2** and **4** lacking hydroxyl groups at the terminal ribose did not induce significant whole cell currents in TRPM2-expressing HEK cells at 100 μmol/L ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a). This was unexpected as *O*-acetyl-ADPR, a product of NAD-dependent histone deacetylases of the Sir2 family, is an effective activator of TRPM2 that binds to the NUDT*H* domain with similar affinity as ADPR, as shown by UV cross-linking experiments and activates TRPM2 with a comparable concentration dependence as ADPR.^[@ref41]^ 2″-*O*-acetyl-ADPR **33**, the product of the deacetylases, undergoes in neutral solution rapid intramolecular transesterification resulting in roughly equal amounts of 2″-*O*-acetyl-ADPR **33** and 3″-*O*-acetyl-ADPR **34**.^[@ref42]^ Either the nucleotide binding site of TRPM2 is indifferent to the position of the acetyl group, which would indicate that neither the 2″- nor the 3″-hydroxyl group is essential as hydrogen bond donor, or there is a specificity for one of the isomers which would mean that only half of the *O*-acetyl-ADPR molecules in solution are effective agonists. Because the latter seems unlikely, this may suggest that the 2″-OH and 3″-OH groups are hydrogen-bond acceptors, a feature that could be retained even when acetylated. We have previously shown that α-1″-*O*-methyl-ADPR and β-1″-*O*-methyl-ADPR ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) do not activate TRPM2, but both inhibit channel activation by ADPR.^[@ref29]^ This indicates that the 1″-hydroxyl group in ADPR could not be masked or that there is no space in this region to accommodate even a relatively small methyl group, without losing agonist activity in contrast to the 2″- and 3″-hydroxyl groups. So why does 3″-deoxy-ADPR **4** not activate the channel? Possible explanations may be that the conformation of the furanose ring or the ratio between the two anomeric forms of the ribose is affected by the absence of the 3″-hydroxyl group in a way that prevents the proper hydrogen bonding necessary for channel activation or that this hydroxyl is required as a hydrogen bond acceptor.

The five-membered ribose sugar ring is puckered because of nonbonded interactions, and the energetically most stable conformation has all substituents as far apart as possible.^[@ref43]^ Thus, the different substitution patterns in the terminal ribose of ADPR, 1″-deoxy-ADPR **2**, 2″-deoxy-ADPR **3**, and 3″-deoxy-ADPR **4**, might be expected to produce differing types of puckering. Extensive analysis of the ribose and 2′-deoxy-ribose rings in RNA and DNA nucleotides has shown that while ribose adopts a primarily C3′-endo configuration, 2′-deoxy-ribose adopts a primarily C2′-endo form.^[@ref44]^ Such changes alter the orientation of the ribose ring substituents, and this may affect the orientation of the substituents and the way they are presented to the binding site, as well as the stability of a given ADPR analogue by bringing nucleophilic hydroxyl groups into proximity for intramolecular attack on the pyrophosphate. Unfortunately, the broad nature of the peaks in the ^1^H NMR spectra of the ADPR analogues means that it is not possible fully to determine the coupling constants and hence to analyze fully each terminal ribose ring conformation and suggests that rapid interconversion between configurations may be taking place in solution.

ADPR is a mixture of terminal ribose α- and β-anomers and it is not known whether one or both anomers activate TRPM2. Analysis of ^1^H NMR spectra demonstrates that both 2″-deoxy-ADPR **3** and 3″-deoxy-ADPR **4** are also mixtures of the α- and β-forms in the following ratios (α/β, 2″-deoxy-ADPR **3**, 1:1.17; 3″-deoxy-ADPR **4**; 1:4). Both analogues still adopt cyclic (as opposed to open chain form) structures for the terminal ribose. Given that both anomers (α- and β-forms) are present in both cases, it would seem unlikely that this could be the sole cause of their observed inactivity.

Surprisingly, di-deoxy ADPR analogues **5** and **6** did not have significant antagonist activity (data not shown). This was unexpected because the potency of our previous antagonist 8-Ph-ADPR (IC~50~ = 11 μM) was improved by the 2′-deoxy modification (8-Ph-2′-deoxy-ADPR IC~50~ = 3 μM).

The recent cryo-EM structures of human TRPM2 show that in the absence of ADPR interactions between the NUDT9*H* domain and MHR1/2 domains of the same and adjacent subunits lock the channel in a closed conformation.^[@ref21]^ Binding of ADPR impacts the conformation of the NUDT9*H* domain of TRPM2 in a way that leads to disengagement of the inter-subunit interactions, priming the channel for full activation by binding of Ca^2+^ ions to a cytosolic site near the pore region.^[@ref21]^ The NUDT9*H* domain of TRPM2 has a bi-lobed structure with the two lobes forming a cleft that is supposed to bind ADPR. While comparison of the apo and the ADPR bound state shows a narrowing of this cleft upon binding of ADPR,^[@ref21]^ the low local resolution of the structure in the NUDT9*H* domain does not currently allow for localization of ADPR in this binding pocket or for identification of the interactions, which would trigger the conformational changes leading to the primed state. In the absence of a high-resolution structure, SAR data therefore remain essential for ligand based drug design. Our current data further support the role of interactions involving the terminal ribose of ADPR in the gating of TRPM2.

Recently, key differences between hTRPM2 and the invertebrate *N. vectensis* variant nvTRPM2 were identified. Thus, two reported synthetic ADPR analogue hTRPM2 antagonists were nvTRPM2 agonists.^[@ref45]^ Moreover, a regulatory function of NUDT9*H* in nvTRPM2 opposed to that in hTRPM2 was uncovered through the action of another synthetic analogue, inosine 5′-diphosphate ribose IDPR. Thus, ADPR analogues, such as those reported here, are at the cutting edge of progress to unravel the mechanism of TRPM2 function.

Conclusions {#sec3}
===========

Building on our previous study that showed the essential role of the terminal ribose of ADPR in gating of the Ca^2+^-permeable, nonselective cation channel TRPM2, we synthesized ribose and 2′-deoxyribose analogues of ADPR **1**--**6**, each lacking one of the hydroxyl groups of the terminal ribose. The convergent synthesis of the targets **1**--**6** consisted of two separate steps: (a) synthesis of particular deoxyribose monophosphates **9**--**12** and (b) coupling analogues **9**--**12** to the AMP and 2′-deoxy-AMP imidazolides **30**--**31**, following the Dabrowski-Tumanski procedure.^[@ref36]^ Such an approach seems to be highly efficient in preparation of such complex molecules as modified ADPR analogues, offering improved yields in our hands compared to pyrophosphate formation using AMP-morpholidates or activation using CDI. While 2″-deoxy-ADPR **3** proved to be unstable, analogues **1**, **2**, **4**, **5**, and **6** showed acceptable stability and were tested electrophysiologically in patch-clamp cell experiments. Neither 1″-deoxy-ADPR **2** nor 3″-deoxy-ADPR **4** was able to activate TRPM2 significantly; instead, both **2** and **4** were weak antagonists of ADPR-mediated TRPM2 activation in whole cell experiments, further highlighting the sensitivity of channel activation to structural changes of the terminal ribose. Thus, 1″-β-*O*-Me-2″,3″-*O*-*i*Pr-ADPR, 1″-deoxy-, and 3″-deoxy-ADPR (**1**, **2** and **4**) were all antagonists of ADPR-mediated Ca^2+^-release in whole cell patch-clamp experiments. Unlike in our previous observations, where including an additional 2′-deoxy-modification generated a more potent TRPM2 antagonist, the corresponding 1″- and 3″, 2′-dideoxy-analogues **5** and **6** were less potent antagonists of TRPM2. Results further highlight the significance of the ADPR terminal ribose for activation of TRPM2 and the use of synthetic ADPR analogues in general. The synthesis of such ADPR analogues as chemical biology tools using the methods outlined here is proving invaluable in the wider TRPM2 field.^[@ref45]^ Further analogues to interrogate individual hydroxyl group stereochemistry or individually mask each of the three terminal hydroxyl groups to probe hydrogen bonding interactions at the TRPM2 binding site will undoubtedly shed more light on the role of the terminal ribose.

Experimental Section {#sec4}
====================

General {#sec4.1}
-------

All reagents and solvents were of commercial quality and were used without further purification, unless described otherwise. Triethylamine was dried over potassium hydroxide, distilled, and then stored over potassium hydroxide pellets. H~2~O was of MilliQ quality. Unless otherwise stated, all reactions were carried out under an inert atmosphere of nitrogen. All ^1^H, ^13^C, and ^31^P NMR spectra of the final compounds were collected, either on a Varian Mercury 400 MHz or Bruker AVANCE III 500 MHz Spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) and all ^1^H and ^13^C NMR assignments are based on COSY, HSQC, HMBC, and DEPT experiments. Abbreviations for splitting patterns are as follows: br, broad; s, singlet; d, doublet; t, triplet; m, multiplet etc. High-resolution time-of-flight mass spectra were obtained on a Bruker Daltonics micrOTOF mass spectrometer using electrospray ionisation. Analytical HPLC analyses were carried out on a Waters 2695 Alliance module equipped with a Waters 2996 Photodiode Array Detector (210--350 nm). The chromatographic system consisted of a Hichrom Guard Column for HPLC and a Phenomenex Synergi 4u MAX-RP 80A column (150 × 4.60 mm), eluted at 1 mL/min with a gradient of MeCN in 0.05 M TEAB. Semi-preparative HPLC was carried out on a Waters 2525 pump with manual FlexInject. The chromatographic system consisted of a Phenomenex Gemini, 5u, C18, 110A column (250 × 10.00 mm), eluted at 5 mL/min.

### 1-*O*-Methyl-2,3-*O*-isopropylidene-β-[d]{.smallcaps}-ribofuranose (**7**)^[@ref30]^ {#sec4.1.1}

Compound **7** was prepared according to the literature from [d]{.smallcaps}-ribose. Yield (4.28 g, 63%). NMR and HRMS confirmed. ^1^H NMR (400 MHz, CDCl~3~): δ 4.93 (s, 1H, H-1), 4.78 (d, *J* = 6.0 Hz, 1H, H-2), 4.54 (d, *J* = 6.0 Hz, 1H, H-3), 4.38 (br s, 1H, H-4), 3.66--3.55 (m, 2H, H-5~a,b~), 3.38 (s, 3H, OCH~3~), 3.19 (br s, 1H, OH), 1.44 (s, 3H, CH~3~), 1.27 (s, 3H, CH~3~).

### Dibenzyl 1-*O*-methyl-2,3-*O*-isopropylidene-β-[d]{.smallcaps}-ribofuranose-5-phosphate (**8**) {#sec4.1.2}

1-*O*-methyl-2,3-*O*-isopropylidene-β-[d]{.smallcaps}-ribofuranose **7** (100 mg, 0.49 mmol) and 5-phenyl-1*H*-tetrazole (143 mg, 0.98 mmol) were co-evaporated with dry toluene (2×). Then, the solid mixture was suspended in dichloromethane (2 mL), and dibenzyl *N*,*N*-diisopropylphosphoramidite (250 μL, 0.669 mmol) was added dropwise. The mixture was stirred at 20 °C for 2 h. TLC analysis (petroleum ether/EtOAc, 2:1 v/v) showed complete phosphitylation. The reaction was cooled to 0 °C, and triethylamine (407 μL, 2.92 mmol) was added followed by aqueous hydrogen peroxide (35%, 109 μL, 1.24 mmol). The resulting mixture was stirred at 20 °C for 1 h. The mixture was diluted with EtOAc (20 mL) and extracted with aqueous Na~2~SO~3~ (10%, w/v). The organic phase was dried (Na~2~SO~4~), solids were removed by filtration, and the solvent was evaporated in vacuo. The crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 0:1, v/v). This procedure afforded the title compound **8** as a colorless liquid (180 mg, 79%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.40--7.31 (m, 10H, Bn-2, 3, 4), 5.10--5.0 (m, 4H, Bn-CH~2~), 4.93 (s, 1H, H-1), 4.60 (dd, 1H, *J* = 6.0 Hz, *J* = 0.4 Hz, H-2), 4.50 (d, 1H, *J* = 6.0 Hz, H-3), 4.28 (dt, 1H, *J* = 6.0 Hz, *J* = 0.4 Hz, H-4), 4.0--3.88 (m, 2H, H-5), 3.26 (s, 3H, OMe), 1.46 and 1.28 (2 × s, 2 × 3H, CH~3~*i*Pr). ^31^P NMR (160 MHz, CDCl~3~): δ −1.23 (s, P). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 135.7 and 135.6 (2 × C-*ipso*-Bn), 128.5 and 127.9 (10 × C-Bn-*o*, *m*, *p*), 112.5 (**C**(CH~3~)), 109.3 (C-1), 84.9 (C-3), 84.6 (d, *J* = 9.0 Hz, C-4), 81.4 (C-2), 69.4 and 69.4 (**CH**~**2**~-Bn), 67.1 (d, *J* = 6.0 Hz, C-5), 55.0 (OMe), 26.3 and 24.9 (CH~3~*i*Pr). HRMS (ES^+^) calcd for C~23~H~29~NaO~8~P, 487.1492 \[M + Na\]^+^; found, 487.1501.

### 1-*O*-Methyl-2,3-*O*-isopropylidene-β-[d]{.smallcaps}-ribofuranose-5-phosphate (**9**) {#sec4.1.3}

Dibenzyl 1-*O*-methyl-2,3-*O*-isopropylidene-β-[d]{.smallcaps}-ribofuranose-5-phosphate **8** (180 mg, 0.39 mmol) was dissolved in MeOH--water (17:3 v/v, 8 mL). After vacuum/argon deoxygenation of the reaction mixture, a catalytic amount of palladium on charcoal (10%, 20 mg) was added. The reaction was stirred under positive pressure of hydrogen atmosphere (balloon) at 20 °C for 5 h. Then, the reaction was flushed with argon and neutralized by addition of TEAB buffer (1 mL, 1 M). The solvent was evaporated and the crude product was co-evaporated (2×) with dry toluene and dried under high-vacuum to give a colourless solid film, compound **9** (1.17 × Et~3~N salt, 122 mg, 82%). ^1^H NMR (400 MHz, CD~3~OD): δ 4.83 (s, 1H, H-1), 4.77 (m, 1H, H-2), 4.53 (d, 1H, *J* = 8.0 Hz, H-3), 4.24--4.18 (m, 1H, H-4), 3.83--3.72 (m, 2H, H-5), 3.24 (s, 3H, OMe), 3.08 (q, 7H, *J* = 8.0 Hz, N**CH**~**2**~CH~3~), 1.37 (t, 3H, CH~3~*i*Pr), 1.27--1.21 (m, 13.5 H, NCH~2~**CH**~**3**~, CH~3~*i*Pr). ^31^P NMR (160 MHz, *d*~4~-MeOD): δ 0.87 (s, P). ^13^C{^1^H}NMR (100 MHz, CD~3~OD): δ 113.3 (**C**(CH~3~)), 110.7 (C-1), 86.9 (d, *J* = 9.0 Hz, C-4), 86.4 (C-3), 83.4 (C-2), 66.3 (d, *J* = 5.0 Hz, C-5), 55.1 (OMe), 47.5 (N**CH**~**2**~CH~3~), 26.7 and 25.0 (CH~3~*i*Pr), 9.2 (NCH~2~**CH**~**3**~). HRMS (ES^--^) calcd for C~9~H~16~O~8~P 283.0588 \[M -- H\]^−^; found 283.0575. (The product was transformed into its tributylammonium salt before the pyrophosphate coupling). Transformation of 9 to mono-tributylammonium salt: The triethylammonium salt of compound **9** (89 mg, 0.23 mmol) was dissolved in water (2 mL) and treated with Dowex D50 (H^+^). Then, the resin was removed by filtration and the solution of **9** (free acid) was titrated with tributylamine (54 μL, 0.23 mmol, 1 equiv, to pH 7). The solution of **9** was freeze-dried overnight to obtain a colorless film, compound **9** (mono-tributylammonium salt, quant.). ^1^H NMR (400 MHz, H~2~O, water suppression): δ 5.09 (s, 1H, H-1), 4.90 (d, 1H, *J* = 5.6 Hz, H-2), 4.65 (d, 1H, *suppressed by H*~2~*O*, H-3), 4.43--4.35 (m, 1H, H-4), 3.89--3.82 (m, 2H, H-5), 3.37 (s, 1H, OMe), 3.15--3.07 (m, 6H, N**CH**~**2**~), 1.69--1.59 (m, 6H, NCH~2~**CH**~**2**~), 1.49 (s, 3H, CH~3~*i*Pr), 1.40--1.30 (m, 9H, N(CH~2~)~2~**CH**~**3**~, CH~3~*i*Pr), 0.95--0.87 (m, 9H, N(CH~2~)~3~**CH**~**3**~). ^31^P NMR (160 MHz, D~2~O): δ 0.14 (s, P). ^13^C{^1^H}NMR (100 MHz, D~2~O): δ 113.2 (**C**(CH~3~)), 108.5 (C-1), 86.4 (C-3), 85.0 (d, *J* = 9.0 Hz, C-4, HSQC), 81.0 (C-2), 65.2 (d, *J* = 7.0 Hz, C-5, HSQC), 54.8 (OMe), 52.8 (N**CH**~**2**~), 25.3 (CH~3~*i*Pr), 25.3 (NCH~2~**CH**~**2**~), 23.7 (CH~3~*i*Pr), 19.3 (N(CH~2~)~2~**CH**~**2**~), 12.8 (N(CH~2~)~3~**CH**~**3**~).

### 2,3-*O*-Isopropylidene-5-*O*-trityl-[d]{.smallcaps}-ribofuranose (**14**) {#sec4.1.4}

2,3-*O*-Isopropylidene-[D]{.smallcaps}-ribofuranose **13** (4 g, 21.1 mmol) was dissolved in pyridine (10 mL). Trityl chloride (7.05 g, 25.3 mmol) was added to the stirred solution, and the mixture was stirred at 20 °C for 16 h. Water (30 mL) was added, and the mixture was stirred additional 10 min. The aqueous phase was extracted with dichloromethane (3×). The combined organic phase was dried with MgSO~4~, solids were removed by filtration, and the solvent was evaporated in vacuo. The crude product was purified by silica gel chromatography petroleum ether/EtOAc (1:0 → 0:1, v/v). This procedure afforded the title compound **14** as a white amorphous solid (5.9 g, 65%). ^1^H NMR^[@ref25]^ (400 MHz, DMSO-*d*~6~): δ 7.42--7.32 and 7.30--7.24 (2 × m, 12 + 3H, *o*, *m*, *p*-Tr), 6.41 (d, 1H, *J* = 4.0 Hz, OH), 5.15 (d, 1H, *J* = 4.0 Hz, H-1), 4.56 (dd, 1H, *J* = 6.0 Hz, *J* = 1.0 Hz, H-2), 4.36 (d, 1H, *J* = 6.0 Hz, H-3), 4.11--4.05 (m, 1H, H-4), 3.16--3.05 (m, 2H, H-5), 1.37 and 1.23 (2 × s, 2 × 3H, CH~3~*i*Pr). HRMS (ES^+^) calcd for C~27~H~28~NaO~5~, 455.1829 \[M + Na\]^+^; found, 455.1842.

### 2,3-*O*-Isopropylidene-5-*O*-trityl-[d]{.smallcaps}-ribitol (**15**) {#sec4.1.5}

2,3-*O*-Isopropylidene-5-*O*-trityl-[d]{.smallcaps}-ribofuranose **14** (5.2 g, 11.98 mmol) was dissolved in EtOH and cooled to 0 °C. Sodium borohydride (460 mg, 12.1 mmol) was added to the solution in three portions over the period of 30 min. The mixture was stirred at 20 °C for 2 h. Water (80 mL) was added, and the solution was carefully acidified with acetic acid to pH 6. Then, the aqueous phase was extracted with dichloromethane (3×). The combined organic phase was dried (Na~2~SO~4~), solids were removed by filtration, and the solvent was evaporated in vacuo. The crude product was purified by Isco-Flash chromatography using CH~2~Cl~2~/acetone (1:0 → 1:1, v/v). This procedure afforded the title compound **15** as an amorphous white solid (4.35 g, 83%). ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.48--7.41 (m, 6H, *o*-Tr), 7.35--7.28 (m, 6H, *m*-Tr), 7.26--7.20 (m, 3H, *p*-Tr), 5.15 (d, *J* = 5.6 Hz, OH-4), 4.80 (t, *J* = 5.6 Hz, OH-1), 4.17--4.10 (m, 1H, H-2), 4.08--4.01 (m, 1H, H-3), 3.78--3.66 (m, 2H, H-4 and H-1~a~), 3.51--3.43 (m, 1H, H-1~b~), 3.15--3.11 (m, 1H, H-5~a~), 3.06--3.01 (m, 1H, H-5~b~), 1.20 (s, 6H, CH~3~*i*Pr). ^13^C{^1^H}NMR (100 MHz, DMSO-*d*~6~): δ 144.0 (3 × C-*ipso*-Tr), 128.4 (6 × C-*o*-Tr), 127.7 (6 × C-*m*-Tr), 126.8 (3 × C-*p*-Tr), 107.4 (**C**(CH~3~)), 85.7 (**C**(Tr)), 78.2 (C-2), 76.4 (C-3), 68.2 (C-4), 66.1 (C-1), 60.0 (C-5), 27.8 and 25.4 (CH~3~*i*Pr). HRMS (ES^+^) calcd for C~27~H~30~NaO~5~, 457.1985 \[M + Na\]^+^; found, 457.2004.

### 1-Deoxy-2,3-*O*-isopropylidene-5-*O*-trityl-[d]{.smallcaps}-ribofuranose (**16**) {#sec4.1.6}

2,3-*O*-Isopropylidene-5-*O*-trityl-[d]{.smallcaps}-ribitol **15** (1.89 g, 4.35 mmol) was dissolved in pyridine (15 mL) and tosyl chloride (2.49 g, 13.06 mmol) was added. The mixture was stirred at 60 °C for 16 h. TLC analysis showed that the reaction was complete. The tosyl chloride surplus was decomposed by addition of water (50 mL) and the aqueous phase was extracted with dichloromethane (3×). The combined organic phase was dried (Na~2~SO~4~), solids were removed by filtration, and the solvent was evaporated in vacuo. The crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 1:1, v/v), affording the title compound **16** as an amorphous white solid (1.44 g, 80%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.44--7.39 (m, 6H, *o*-Tr), 7.33--7.27 (m, 6H, *m*-Tr), 7.26--7.21 (m, 3H, *p*-Tr), 4.91--4.86 (m, 1H, H-2), 4.65 (dd, 1H, *J* = 6.4 Hz, *J* = 1.2 Hz, H-3), 4.24--4.19 (m, 1H, H-4), 4.15 (dd, 1H, *J* = 10.4 Hz, *J* = 4.4 Hz, H-1~a~), 4.05 (dd, 1H, *J* = 10.0 Hz, *J* = 1.0 Hz, H-1~b~), 3.27 (dd, 1H, *J* = 10.0 Hz, J = 4.0 Hz, H-5~a~), 3.11 (dd, 1H, *J* = 10.0 Hz, *J* = 4.4 Hz, H-5~b~), 1.51 and 1.34 (2 × s, 6H, CH~3~*i*Pr). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 143.6 (3 × C-*ipso*-Tr), 128.6 (6 × C-*o*-Tr), 127.8 (6 × C-*m*-Tr), 127.2 (3 × C-*p*-Tr), 112.3 (**C**(CH~3~)), 87.1 (**C**(Tr)), 84.0 (C-4), 83.0 (C-3), 81.6 (C-2), 74.3 (C-1), 64.5 (C-5), 26.6 and 25.1 (CH~3~*i*Pr). HRMS (ES^+^) calcd for C~27~H~28~NaO~4~, 439.1880 \[M + Na\]^+^; found, 439.1868.

### 1-Deoxy-2,3-*O*-isopropylidene-[d]{.smallcaps}-ribofuranose (**17**) {#sec4.1.7}

1-Deoxy-2,3-*O*-isopropylidene-5-*O*-trityl-[d]{.smallcaps}-ribofuranose **16** (100 mg, 0.24 mmol) was dissolved in diethylether--HCOOH (2 mL, 1:1, v/v) and stirred at 20 °C for 16 h. TLC analysis (petroleum ether/EtOAc, 1:1, v/v) indicated the complete conversion of reaction and the mixture was evaporated to dryness. The dry residue was suspended in water and the suspension was filtered through a cotton pad. Evaporation of water afforded the title compound **17** as a colorless viscous liquid (14.5 mg, 32%). ^1^H NMR (400 MHz, CDCl~3~): δ 4.83--4.78 (m, 1H, H-2), 4.59 (dd, 1H, *J* = 6.4 Hz, *J* = 2.0 Hz, H-3), 4.13--4.09 (m, 1H, H-4), 3.98--3.95 (m, 2H, H-1~a,b~), 3.65 (dd, 1H, *J* = 11.6 Hz, *J* = 4.0 Hz, H-5~a~), 3.58 (dd, 1H, *J* = 11.6 Hz, *J* = 6.4 Hz, H-5~b~), 1.51 and 1.33 (2 × s, 6H, CH~3~*i*Pr). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 113.0 (**C**(CH~3~)), 84.8 (C-4), 81.8 (C-3), 81.0 (C-2), 72.8 (C-1), 61.8 (C-5), 26.7 and 25.0 (CH~3~*i*Pr). HRMS (ES^+^) calcd for C~8~H~14~NaO~4~ 197.0784 \[M + Na\]^+^; found 197.0791.

### 1-Deoxy-2,3-*O*-isopropylidene-[d]{.smallcaps}-ribofuranose-5-*O*-di-*tert*-butylphosphate (**18**) {#sec4.1.8}

1-Deoxy-2,3-*O*-isopropylidene-[d]{.smallcaps}-ribofuranose **17** (94 mg, 0.49 mmol) and 5-phenyl-1*H*-tetrazole (145 mg, 0.99 mmol) were co-evaporated with dry toluene (2×). Then, the dry mixture was dissolved in dichloromethane (2 mL), and di-*tert*-butyl *N*,*N*-diisopropylphosphoramidite (234 μL, 0.74 mmol) was added dropwise. The mixture was stirred at 20 °C for 2 h after which TLC analysis (petroleum ether/EtOAc, 2:1, v/v) showed the reaction was complete. It was cooled to 0 °C and triethylamine (411 μL, 2.97 mmol) was added, followed by hydrogen peroxide (35% aq, 109 μL, 1.24 mmol). The resulting mixture was stirred at 20 °C for 1 h. The mixture was diluted with EtOAc (20 mL) and extracted with aqueous Na~2~SO~3~ (10%, w/v). The organic phase was dried (Na~2~SO~4~), solids were filtered off, and the solvent was evaporated in vacuo. The crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 0:1, v/v), to afford the title compound **18** as a colorless liquid (74 mg, 41%). ^1^H NMR (400 MHz, CDCl~3~): δ 4.85--4.81 (m, 1H, H-2), 4.76 (dd, 1H, *J* = 6.4 Hz, *J* = 1.2 Hz, H-3), 4.23--4.18 (m, 1H, H-4), 4.2--3.94 (m, 4H, H-1, H-5), 1.51 (s, 3H, CH~3~*i*Pr), 1.48 (s, 18H, CH~3~*t*Bu), 1.33 (s, 3H, CH~3~*i*Pr). ^31^P NMR (160 MHz, CDCl~3~): δ −10.1 (s, P). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 112.6 (**C**(CH~3~)), 83.1 (d, *J* = 8.0 Hz, **C**(*t*Bu)), 82.6 (d, *J* = 7.0 Hz, C-4), 82.3 (C-3), 81.2 (C-2), 73.9 (C-1), 66.6 (d, *J* = 7.0 Hz, C-5), 29.8--29.7 (m, CH~3~*t*Bu), 26.5 and 24.9 (CH~3~*i*Pr)). HRMS (ES^+^) calcd for C~16~H~31~NaO~7~P, 389.1700 \[M + Na\]^+^; found, 389.1699.

### Tributylammonium 1-deoxy-2,3-*O*-isopropylidene-[d]{.smallcaps}-ribofuranose-5-phosphate (**10**) {#sec4.1.9}

1-Deoxy-2,3-*O*-isopropylidene-[D]{.smallcaps}-ribosfuranose-5-*O*-di-*tert*-butyl phosphate **18** (36 mg, 0.098 mmol) was dissolved in aqueous methanol (1:1, v/v, 2 mL), and the solution was cooled to 0 °C. Trifluoroacetic acid (2 mL) was added dropwise and the solution was allowed to warm up to 20 °C and stirred for an additional 4 h. The solution was evaporated to dryness and the residue co-evaporated with water (3×) and with methanol (3×). The procedure afforded the pure phosphate derivative as a colorless gum (21 mg, quantitative) which was directly dissolved in water (2 mL), neutralized with tributylamine (33 μL, 0.14 mmol), the solvent evaporated, and the residue co-evaporated with EtOH (2×). The title compound **10** was obtained as the mono-tributylammonium salt (18.7 mg, 49%). ^1^H NMR (400 MHz, MeOH): δ 4.21--4.16 (m, 1H, H-2), 4.12--4.07 (m, 1H, H-3), 4.03--3.87 (m, 4H, H-1~a~, 4, 5~a,b~), 3.69 (dd, 1H, *J* = 9.6 Hz, *J* = 4.0 Hz, H-1~b~), 3.10--3.03 (m, 6H, NCH~2~), 1.73--1.64 (m, 6H, NCH~2~**CH**~**2**~), 1.41 (m, 6H, N(CH~2~)~2~**CH**~**2**~), 1.00 (t, 9H, *J* = 7.6 Hz, CH~3~Bu). ^31^P NMR (160 MHz, MeOH): δ 1.09 (s, P). ^13^C{^1^H}NMR (100 MHz, MeOH): δ 83.3 (d, *J* = 8.0 Hz, C-4), 73.7 (C-1), 73.6 (C-3), 72.5(C-2), 66.3 (d, *J* = 5.0 Hz, C-5), 54.0 (N**C**H~2~), 27.0 (NCH~2~**C**H~2~), 21.0 (N(CH~2~)~2~**C**H~2~), 14.0 (CH~3~Bu). HRMS (ES^--^) calcd for C~5~H~11~O~7~P, 213.0170 \[M -- H\]^−^; found, 213.0162.

### 2-Deoxy-[d]{.smallcaps}-ribofuranose-5-phosphate sodium Salt (**19**) {#sec4.1.10}

Compound **19** (sodium salt) was purchased from Sigma-Aldrich (UK) and found to be a mixture of α and β anomers in the ratio 1/1.17 α/β). ^1^H NMR (500 MHz, D~2~O): δ 5.52--5.47 (m, 1.6H, H-1α, β, deuterium exchange), 4.51--4.46 (m, 1H, H-3β), 4.38--4.34 (m, 1H, H-3α), 4.25--4.20 (m, 1H, 4α), 4.04--3.99 (m, 1H, H-4β), 3.85--3.81 (m, 2H, H-5β), 3.81--3.75 (m, 2H, H-5α), 2.51--2.42 (m, 1H, H-2α), 2.22--2.14 (m, 2H, H-2β), 1.91--1.83 (m, 1H, H-2α). ^31^P NMR (202 MHz, D~2~O): δ 3.65 (P-β) and 3.68 (P-α). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 98.4 (C-1β), 98.0 (C-1α), 84.9 (d, *J* = 10.08 Hz, C-4β), 84.6 (d, *J* = 8.82 Hz, C-4α), 71.6 (C-3β), 71.1 (C-3α), 64.6 (d, *J* = 5.0 Hz, C-5β), 63.7 (d, *J* = 3.8 Hz, C-5α), 40.8 (C-2β), 40.6 (C-2α). Compound **19** was transformed to its tributylammonium salt.

### 2-Deoxy-[D]{.smallcaps}-ribofuranose-5-phosphate Mono-tributylammonium Salt (**11**) {#sec4.1.11}

Commercially available 2-deoxy-[D]{.smallcaps}-ribofuranose-5-phosphate sodium salt **19** (Sigma-Aldrich) (8 mg, 0.029 mmol) was dissolved in water (2 mL) and acidified to pH 1--2 by using the ion-exchange resin Dowex (D50 H^+^). The resin was filtered off and the free phosphate was neutralized by addition of one equivalent of tributylamine (6.9 μL, 0.029 mmol). The aqueous solution was freeze-dried (quant.). (NMR analysis showed partial decomposition (approx. 20--30%), of 2′-deoxyribose. The compound itself is sensitive to basic conditions (pH 9)). ^1^H NMR (500 MHz, D~2~O): δ 5.50--5.47 (m, 0.54H, H-1β), 5.43--5.41 (dd, 0.46H, *J* = 5.5 Hz, *J* = 2.5 Hz, H-1α), 4.43--4.39 (m, 0.53H, H-3β), 4.29--4.25 (m, 0.47H, H-3α), 4.15--4.1 (m, 0.46H, H-4α), 4.02--3.97 (m, 0.7H, H-5β), 3.94--3.85 (m, 1.32H, H-4β, 5α, 5β), 3.84--3.77 (m, 0.52H, H-5α), 3.09--3.01 (m, 10H, N**CH**~**2**~(CH~2~)~2~CH~3~), 2.38--2.30 (m, 0.5H, H-2α), 2.12--1.99 (m, 1H, H-2β), 1.86--1.79 (m, 0.5H, H-2α), 1.72--1.60 (m, 10H, NCH~2~**CH**~**2**~CH~2~CH~3~), 1.47--1.35 (m, 10H, NCH~2~CH~2~**CH**~**2**~CH~3~), 1.04--0.94 (m, 15H, NCH~2~(CH~2~)~2~**CH**~**3**~). ^31^P NMR (202 MHz, D~2~O): δ 1.10 (P-β) and 1.03 (P-α). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 100.0 (C-1β), 99.5 (C-1α), 86.3 (d, *J* = 8.4 Hz, C-4β), 85.6 (d, *J* = 8.7 Hz, C-4α), 73.5 (C-3β), 73.0 (C-3α), 67.3 (d, *J* = 5.4 Hz, C-5β), 66.1 (d, *J* = 5.3 Hz, C-5α), 53.8 (N**CH**~**2**~(CH~2~)~2~CH~3~), 43.0 (C-2β), 42.6 (C-2α), 26.9 (NCH~2~**CH**~**2**~CH~2~CH~3~), 21.1 (NCH~2~CH~2~**CH**~**2**~CH~3~), 14.0 (NCH~2~(CH~2~)~2~**CH**~**3**~).

### 1,2-*O*-Isopropylidene-[d]{.smallcaps}-xylofuranose (**20**)^[@ref34]^ {#sec4.1.12}

Finely powdered [d]{.smallcaps}-xylose (10 g, 67 mmol) was suspended in acetone (260 mL) containing sulphuric acid (10 mL) and stirred for 30 min until it was dissolved. The solution was cooled to 0 °C, and a solution of Na~2~CO~3~ (13 g in 112 mL H~2~O) was added. The mixture was stirred at 20 °C for 1 h, and then solid Na~2~CO~3~ (7 g) was added. The slurry was stirred at 20 °C for an further 30 min. Solids were removed by filtration and washed with acetone. Acetone was evaporated, and the water phase was extracted with EtOAc (3×) and dried with Na~2~SO~4~. Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 1:1, v/v) afforded the title compound **20** as a colorless viscous oil (4.35 g, 34%) and doubly protected 1, 2-*O*-isopropylidene-3,5-*O*-isopropylidene-[d]{.smallcaps}-xylofuranose (3.29 g, 21%).^[@ref34]1^H NMR (400 MHz, CDCl~3~): δ 5.98 (d, 1H, *J* = 3.6 Hz, H-1), 4.52 (d, 1H, *J* = 3.6 Hz, H-2), 4.32 (d, 1H, *J* = 2.4 Hz, H-4), 4.19--4.11 (m, 2H, H-3, 5~a~), 4.05 (dd, 1H, *J* = 12.4 Hz, *J* = 2.4 Hz, H-5~b~), 1.48 and 1.32 (CH~3~*i*Pr). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 112.0 (**C**(CH~3~)~2~), 105.1 (C-1), 85.9 (C-2), 78.7 (C-3), 77.3 (C-4), 61.5 (C-5), 26.9 and 26.3 (CH~3~*i*Pr). HRMS (ES^+^) calcd for C~8~H~14~NaO~5~, 213.0733 \[M + Na\]^+^; found, 213.0787.

### 5-*O*-*tert*-Butyl(diphenyl)silyl-1,2-*O*-isopropylidene-[d]{.smallcaps}-xylofuranose (**21**) {#sec4.1.13}

1,2-*O*-Isopropylidene-[d]{.smallcaps}-xylofuranose **20** (3.63 g, 19.08 mmol) and DMAP (5 mg) were dissolved in pyridine (15 mL). *tert*-Butyl(diphenyl)silyl chloride (4.89 mL, 19.08 mmol) was added dropwise, and the solution was stirred at 20 °C for 16 h. Solvent was evaporated and the crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 1:1, v/v). This procedure afforded the title compound **21** as a white solid (6.58 g, 83%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.74--7.65 (m, 4H, *o*-Ph), 7.48--7.38 (m, 6H, *m*, *p*-Ph), 6.00 (d, 1H, *J* = 3.6 Hz, H-1), 4.54 (d, 1H, *J* = 3.6 Hz, H-2), 4.39--4.35 (m, 1H, H-4), 4.16--4.12 (m, 1H, H-3), 4.12--4.09 (m, 2H, H-5), 3.99 (d, 1H, *J* = 2.4 Hz, 3-OH), 1.47 and 1.33 (CH~3~*i*Pr), 1.06 (CH~3~*t*Bu). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 135.8 and 135.7 (*o*-Ph), 132.6 and 132.1 (C-*ipso*-Ph), 130.2 and 128.1 (2 × d, *J* = 2.2 Hz, *J* = 1.7 Hz, *m*, *p*-Ph), 111.8 (**C**(CH~3~)~2~), 105.2 (C-1), 85.6 (C-2), 78.6 (C-3), 77.0 (C-4, obstructed by CDCl~3~ signal), 62.9 (C-5), 27.0 and 26.3 (CH~3~*i*Pr), 26.9 (CH~3~*t*Bu), 19.2 (**C**(CH~3~)~3~). HRMS (ES^+^) calcd for C~24~H~32~NaO~5~Si, 451.1911 \[M + Na\]^+^; found, 451.1929.

### 5-*O*-*tert*-Butyl(diphenyl)silyl-1,2-*O*-isopropylidene-3-thiocarbonylimidazolo-[d]{.smallcaps}-xylofuranose (**22**) {#sec4.1.14}

A mixture of 5-*O*-*tert*-butyl(diphenyl)silyl-1,2-*O*-isopropylidene-[d]{.smallcaps}-xylofuranose **21** (3.0 g, 7.01 mmol) and 1,1′-thiocarbonyldiimidazole (2.37 g, 13.32 mmol) was gently refluxed in dichloroethane at 85 °C for 2 h. The solvent was evaporated, and the crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 0:1, v/v) to afford the title compound **22** as a white solid (2.4 g, 63%). ^1^H NMR (400 MHz, CDCl~3~): δ 8.24--8.21 (m, 1H, imidazole), 7.64--7.60 (m, 2H, Ph), 7.55--7.51 (m, 2H, Ph), 7.47 (t, 1H, *J* = 1.6 Hz, imidazole), 7.46--7.33 (m, 4H, Ph), 7.29--7.23 (m, 2H, Ph), 7.04 (q, 1H, *J* = 0.8 Hz, imidazole), 5.98 (d, 1H, *J* = 2.8 Hz, H-3), 5.94 (d, 1H, *J* = 4.0 Hz, H-1), 4.72 (d, 1H, *J* = 4.0 Hz, H-2), 4.61 (dq, 1H, *J* = 8.8 Hz, *J* = 2.8 Hz, H-4), 4.02 (dd, 1H, *J* = 10.0 Hz, *J* = 4.4 Hz, H-5~a~), 3.82 (dd, 1H, *J* = 10.0 Hz, *J* = 8.4 Hz, H-5~b~), 1.60 and 1.36 (2 × s, 2 × 3H, CH~3~*i*Pr), 1.02 (s, 9H, CH~3~*t*Bu). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 182.6 (C=S), 136.9 (imidazole), 135.6 and 135.4 (Ph), 132.8 and 132.7 (C-*ipso*-Ph), 131.2 (imidazole), 130.1 (Ph), 127.9 and 127.8 (Ph), 117.8 (Imz), 112.8 (**C**(CH~3~)~2~), 105.0 (C-1), 84.2 (C-3), 82.7 (C-2), 78.9 (C-4), 60.3 (C-5), 26.9 (CH~3~*t*Bu), 26.7 and 26.4 (CH~3~*i*Pr), 19.2 (**C**(CH~3~)~3~). HRMS (ES^+^) calcd for C~28~H~34~N~2~NaO~5~SSi, 561.1850 \[M + Na\]^+^; found, 561.1837.

### 5-*O*-*tert*-Butyl(diphenyl)silyl-1,2-*O*-isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose (**23**) {#sec4.1.15}

Tributyltin hydride (1.07 mL, 3.99 mmol) was added into boiling toluene (90 mL) under argon followed by AIBN (13 mg, 0.08 mmol). Then, 5-*O*-*tert*-butyl(diphenyl)silyl-1,2-*O*-isopropylidene-3-thiocarbonylimidazolo-[d]{.smallcaps}-xylofuranose **22** (1.26 g, 2.35 mmol) was added dropwise in toluene (20 mL). The mixture was refluxed for 3 h. Solvent was evaporated and the crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 0:1, v/v) to afford the title compound **23** as a white solid (731 mg, 76%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.71 (m, 4H, *o*-Ph), 7.45--7.35 (m, 6H, *m*, *p*-Ph), 5.83 (d, 1H, *J* = 3.6 Hz, H-1), 4.75 (t, 1H, *J* = 4.0 Hz, H-2), 4.33 (dq, 1H, *J* = 10.4 Hz, *J* = 4.0 Hz, H-4), 3.82 (dd, 1H, *J* = 11.2 Hz, *J* = 4.4 Hz, H-5~a~), 3.76 (dd, 1H, *J* = 11.2 Hz, *J* = 4.0 Hz, H-5~b~), 3.08 (dd, 1H, *J* = 13.6 Hz, *J* = 4.8 Hz, H-3~a~), 1.88 (ddd, 1H, *J* = 13.6 Hz, *J* = 10.4 Hz, *J* = 4.8 Hz, H-3~b~), 1.52 and 1.34 (2 × s, 2 × 3H, CH~3~*i*Pr), 1.06 (s, 9H, CH~3~*t*Bu). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 135.8 and 135.7 (*o*-Ph), 133.7 and 133.5 (C-*ipso*-Ph), 129.8 and 129.8 (*p*-Ph), 127.8 and 127.8 (*m*-Ph), 111.3 (**C**(CH~3~)~2~), 105.9 (C-1), 80.6 (C-2), 78.7 (C-4), 64.9 (C-5), 35.1 (C-3), 27.1 (CH~3~*i*Pr), 27.0 (CH~3~*t*Bu), 26.5 (CH~3~*i*Pr), 19.4 (**C**(CH~3~)~3~). HRMS (ES^+^) calcd for C~24~H~32~NaO~4~Si, 435.1962 \[M + Na\]^+^; found, 435.1995.

### 1,2-*O*-Isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose (**24**) {#sec4.1.16}

A mixture of TBAF·3H~2~O (1.55 g, 5.0 mmol) and acetic acid (300 μL, 5.25 mmol) in DMF (10 mL) was stirred at room temperature for 30 min. The mixture was cooled to 0 °C and 5-*O*-*tert*-butyl(diphenyl)silyl-1,2-*O*-isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose **23** (687 mg, 1.67 mmol) was added dropwise in DMF (5 mL). The resulting mixture was stirred at 20 °C for 3 h. Solvent was evaporated and the crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 0:1, v/v). This procedure afforded the title compound **24** as white solid (260 mg, 82%). ^1^H NMR (400 MHz, CDCl~3~): δ 5.79 (d, 1H, *J* = 3.6 Hz, H-1α), 4.73 (t, 1H, *J* = 4.4 Hz, H-2), 4.31 (dtd, 1H, *J* = 10.8 Hz, *J* = 4.4 Hz, *J* = 3.2 Hz, H-4), 3.84 (dd, 1H, *J* = 12.0 Hz, *J* = 2.8 Hz, H-5~a~), 3.54 (dd, 1H, *J* = 12.0 Hz, *J* = 4.4 Hz, H-5~b~), 1.97 (dd, 1H, *J* = 13.6 Hz, *J* = 4.8 Hz, H-3~a~), 1.85--1.76 (m, 1H, H-3~b~), 1.48 and 1.29 (2 × s, 2 × 3H, CH~3~*i*Pr). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 111.4 (**C**(CH~3~)~2~), 105.7 (C-1α), 80.9 (C-2), 78.7 (C-4), 63.1 (C-5), 34.0 (C-3), 26.9 and 26.3 (CH~3~*i*Pr). HRMS (ES^+^) calcd for C~8~H~14~NaO~4~, 197.0784 \[M + Na\]^+^; found, 197.0793.

### 1,2-*O*-Isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose-5-*O*-di-*tert*-butylphosphate (**25**) {#sec4.1.17}

1,2-*O*-Isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose **24** (100 mg, 0.52 mmol) and 5-phenyl-1*H*-tetrazole (154 mg, 1.05 mmol) were co-evaporated with dry toluene (2×). The solid mixture was then dissolved in dichloromethane (2 mL) and di-*tert*-butyl *N*,*N*-diisopropylphosphoramidite (249 μL, 0.79 mmol) was added dropwise. The mixture was stirred at 20 °C for 2 h. TLC analysis (petroleum ether/EtOAc, 2:1, v/v) showed complete phosphitylation. The reaction was cooled to 0 °C and triethylamine (437 μL, 3.15 mmol) added followed by hydrogen peroxide (35% aq, 116 μL, 1.32 mmol). The resulting mixture was stirred at 20 °C for 1 h. The mixture was diluted with EtOAc (20 mL) and extracted with aqueous Na~2~SO~3~ (10%, w/v). The organic phase was dried (Na~2~SO~4~), solids were filtered off, and the solvent was evaporated in vacuo. The crude product was purified by Isco-Flash chromatography using petroleum ether/EtOAc (1:0 → 0:1, v/v), followed by a second chromatography in dichloromethane/acetone (1:0 → 1:1, v/v). This procedure afforded the title compound **25** as a colorless viscous liquid (97 mg, 50%). ^1^H NMR (400 MHz, CDCl~3~): δ 5.81 (d, 1H, *J* = 4.0 Hz, H-1), 4.73 (t, 1H, *J* = 4.4 Hz, H-2), 4.04 (ddd, 1H, *J* = 8.8 Hz, *J* = 4.4 Hz, *J* = 1.2 Hz, H-4), 4.12--4.06 (m, 1H, H-5a), 4.02--3.96 (m, 1H, H-5~b~), 2.1 (dd, 1H, *J* = 13.6 Hz, *J* = 4.8 Hz, H-3~a~), 1.84--1.76 (m, 1H, H-3~b~), 1.50 (s, 3H, CH~3~*i*Pr), 1.48 (s, 9H, CH~3~*t*Bu) 1.31 (s, 3H, CH~3~*i*Pr). ^31^P NMR (160 MHz, CDCl~3~): δ −9.91 (s, phosphate). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 111.4 (**C**(CH~3~)~2~), 105.8 (C-1), 82.7 and 82.6 (2 × d, *J* = 2.1 Hz, **C**(CH~3~)~3~), 80.7 (C-2), 76.6 (d, *J* = 8.7 Hz, C-4), 67.0 (d, *J* = 6.0 Hz, C-5), 35.2 (C-3), 30.01 and 29.97 (2 × CH~3~*t*Bu), 27.0 and 26.4 (2 × CH~3~*i*Pr). HRMS (ES^+^) calcd for C~16~H~32~O~7~P, 367.1880 \[M + H\]^+^; found, 367.1877; calcd for C~16~H~31~NaO~7~P, 389.1700 \[M + Na\]^+^; found, 389.1737.

### 1,2-*O*-Isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose-5-*O*-dibenzylphosphate (**26**) {#sec4.1.18}

1,2-*O*-Isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose **24** (120 mg, 0.63 mmol) and 5-phenyl-1*H*-tetrazole (185 mg, 1.26 mmol) were co-evaporated with dry toluene (2×). Then, the solid mixture was dissolved in dichloromethane (3 mL) and dibenzyl *N*,*N*-diisopropylphosphoramidite (353 μL, 0.95 mmol) was added dropwise. The mixture was stirred at 20 °C for 2 h. TLC analysis (petroleum ether/EtOAc, 2/1, v/v) showed complete phosphitylation. The reaction was cooled to 0 °C and triethylamine (524 μL, 3.79 mmol) added followed by hydrogen peroxide (35% aq, 139 μL, 1.58 mmol). The resulting mixture was stirred at 20 °C for 1 h. The mixture was diluted with EtOAc (20 mL) and extracted with Na~2~SO~3~ (10% aq, w/v). The organic phase was dried (Na~2~SO~4~), solids were removed by filtration, and the solvent was evaporated in vacuo. The crude product was purified by Isco-Flash chromatography using dichloromethane/acetone (1:0 → 1:1, v/v) followed by a second chromatography in petroleum ether/EtOAc (1:0 → 0:1, v/v) to afford the title compound **26** as a colorless viscous liquid (218 mg, 73%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.37--7.32 (m, 10H, Bn), 5.76 (d, *J* = 3.6 Hz, H-1), 5.10--5.00 (m, 4H, **CH**~**2**~Bn), 4.68 (t, 1H, *J* = 4.4 Hz, H-2), 4.35 (ddd, 1H, *J* = 8.8 Hz, *J* = 4.4 Hz, *J* = 0.8 Hz, H-4), 4.16 (dq, 1H, *J* = 3.6 Hz, *J* = 2.8 Hz, H-5~a~), 4.00 (dq, 1H, *J* = 4.4 Hz, *J* = 2.8 Hz, H-5~b~), 2.00 (dd, 1H, *J* = 13.2 Hz, *J* = 4.4 Hz, H-3~a~), 1.72--1.64 (m, 1H, H-3~b~), 1.48 and 1.31 (2 × s, 2 × 3H, CH~3~*i*Pr). ^31^P NMR (160 MHz, CDCl~3~): δ −1.00 (s, phosphate). ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 136.0 (d, *J* = 2.0 Hz, C-*ipso*-Bn), 135.9 (d, *J* = 3.0 Hz, C-*ipso*-Bn), 128.8--128.7 and 128.2--128.1 (2 × m, C-Bn-*o*, *m*, *p*), 111.5 (**C**(CH~3~)~2~), 105.8 (C-1), 80.5 (C-2), 76.4 (d, *J* = 8.0 Hz, C-4), 69.6 and 69.5 (2 × d, *J* = 1.3 Hz and *J* = 1.4 Hz, **CH**~**2**~Bn), 68.8 (d, *J* = 5.6 Hz, C-5), 34.7 (C-3), 27.0 and 26.3 (**CH**~**3**~*i*Pr). HRMS (ES^+^) calcd for C~22~H~28~O~7~P, 435.1567 \[M + H\]^+^; found, 435.1571; calcd for C~22~H~27~NaO~7~P, 457.1387 \[M + Na\]^+^; found, 457.1392.

### 3-Deoxy-[d]{.smallcaps}-ribofuranose-5-*O*-dibenzylphosphate (**27**) {#sec4.1.19}

An aqueous solution (4 mL) of 1, 2-*O*-isopropylidene-3-deoxy-[d]{.smallcaps}-ribofuranose-5-*O*-dibenzylphosphate **26** (67 mg, 0.154 mmol) was cooled to 0 °C and trifluoroacetic acid (4 mL) was added. The solution was stirred at 0 °C for 1.5 h and then allowed to warm to 20 °C. The solvent was evaporated in vacuo at 30 °C and co-evaporated with water. Crude material was purified by silica gel chromatography using petroleum ether/EtOAc (1:0 → 0:1, v/v) to give a colorless solid (mixture of α/β anomers 1:4, 41 mg, 68%). ^1^H NMR (400 MHz, CD~3~OD): δ 7.39--7.35 (m, 10H, Bn), 5.18 (s, 0.2H, C-1α), 5.17 (s, 0.8H, C-1β), 5.09--5.04 (m, 4H, **CH**~**2**~Bn), 4.45--4.39 (m, 0.8H, H-4β), 4.39--4.35 (m, 0.2H, H-4α), 4.13--4.07 (m, 1H, H-2α, β), 4.06--3.99 (m, 1.8H, H-5α~a~, β~a,b~), 3.90 (ddd, 0.2H, *J* = 12.8 Hz, *J* = 5.6 Hz, *J* = 4.0 Hz, H-5α~b~), 1.96--1.85 (m, 2H, H-3α, β). ^31^P NMR (160 MHz, CD~3~OD): δ −1.30 (s, α-phosphate), −1.54 (s, β-phosphate). ^13^C{^1^H}NMR (100 MHz, CD~3~OD): δ 137.2 and 137.2 (2 × C-*ipso*-Bn), 129.8--129.7 and 129.3--129.2 (2 × m, 10 × C-Bn-*o*, *m*, *p*), 104.3 (C-1β), 98.4 (C-1α), 78.6 (d, *J* = 6.2 Hz, C-4β), 77.1 (C-2β), 75.8 (d, *J* = 6.2 Hz, C-4α), 72.4 (d, *J* = 4.8 Hz, C-5β), 72.2 (C-2α), 71.0 (d, *J* = 4.8 Hz, C-5α), 70.9--70.8 (m, **CH**~**2**~Bn), 34.7 (C-3β), 33.9 (C-3α). HRMS (ES^+^) calcd for C~19~H~24~O~7~P, 395.1254 \[M + H\]^+^; found, 395.1256; calcd for C~19~H~23~NaO~7~P, 417.1074 \[M + Na\]^+^; found, 417.1079.

### 3-Deoxy-[d]{.smallcaps}-ribofuranose-5-phosphate Tributylammonium Salt (**12**) {#sec4.1.20}

3-Deoxy-[d]{.smallcaps}-ribofuranose-5-*O*-dibenzylphosphate **27** (39 mg, 0.098 mmol) was dissolved in MeOH--water (8 mL, 17:3 v/v). After vacuum/argon deoxygenation of the reaction mixture, palladium on charcoal (Pd/C 10%, 10 mg) was added. The reaction was stirred under positive pressure of hydrogen atmosphere (balloon) at 20 °C for 4 h. Then, the reaction was flushed with argon and solids were filtered off and washed with water. The aqueous solution (pH 1--2) was carefully titrated by portionwise addition of tributylamine (5 × 4 μL, 0.084 mmol, pH 6--7). The solvent was evaporated, and the crude product was co-evaporated with dry toluene (2×) and dried under high vacuum for 16 h to give a colorless solid film, compound **12** (mixture of α/β anomers 1:4, 1 × Bu~3~N salt, 29 mg, 67%). ^1^H NMR (500 MHz, CD~3~OD): δ 5.20 (d, 0.2H, *J* = 4.5 Hz, H-1α), 5.12 (s, 0.8H, H-1β), 4.48--4.41 (m, 0.8H, H-4β), 4.41--4.36 (m, 0.2H, H-4α), 4.25--4.20 (m, 0.2H, H-2α), 4.08 (d, 0.8H, *J* = 4.5 Hz, H-2β), 3.96--3.84 (m, 1.6H, H-5β), 3.83--3.79 (m, 0.4H, H-5α), 3.14--3.08 (m, 6H, NCH~2~), 2.12 (ddd, 0.2H, *J* = 12.5 Hz, *J* = 5.5 Hz, *J* = 2.5 Hz, H-3α~a~), 2.04 (ddd, 0.8H, *J* = 13.5 Hz, *J* = 8.5 Hz, *J* = 5.0 Hz, H-3β~a~), 2.01--1.97 (m, 0.2H, H-3α~b~), 0.92 (dd, 0.8H, *J* = 14.0 Hz, *J* = 7.0 Hz, H-3β~a~), 1.73--1.64 (m, 6H, NCH~2~**CH**~**2**~), 1.47--1.38 (m, 6H, N(CH~2~)~2~**CH**~**2**~), 10.14 (t, 9H, *J* = 7.5 Hz, N(CH~2~)~3~**CH**~**3**~). ^31^P NMR (202 MHz, CD~3~OD): δ 1.04 (s, α-phosphate), 0.97 (s, β-phosphate). ^13^C{^1^H}NMR (126 MHz, CD~3~OD): δ 104.3 (C-1β), 98.2 (C-1α), 79.7 (d, *J* = 8.8 Hz, C-4β), 77.4 (C-2β), 76.8 (d, *J* = 8.8 Hz, C-4α), 72.3 (C-2α), 69.7 (d, *J* = 5.03 Hz, C-5β), 68.4 (d, *J* = 5.0 Hz, C-5α), 53.8 (N**CH**~**2**~), 35.3 (C-3β), 34.3 (C-3α), 26.8 (NCH~2~**CH**~**2**~), 21.0 (N(CH~2~)~2~**CH**~**2**~), 14.0 (N(CH~2~)~3~**CH**~**3**~). HRMS (ES^--^) calcd for C~5~H~10~O~7~P, 213.0170 \[M -- H\]^−^; found, 213.0159.

### AMP Imidazolide: Adenosine-5′-phosphoryl Imidazolide (**30**) {#sec4.1.21}

AMP sodium salt (50 mg, 0.128 mmol, Sigma-Aldrich) was dissolved in water (2 mL) and treated with Dowex D50 (H^+^) until all the phosphate was transformed to free acid (pH 1--2). Then, the resin was filtered off and washed with water, and the solution of AMP (free acid) was titrated with tributylamine (30 μL, 0.13 mmol, 1 equiv, pH 7). The solution of adenosine-5′-phosphate mono-tributylammonium salt (**28**) was freeze-dried to obtain a light white powder (quantitative).

AMP tributylammonium salt (15 mg, 0.028 mmol) and imidazole (19 mg, 0.28 mmol) were co-evaporated with EtOH (2×) and with toluene (2×). Aldrithiol (18.6 mg, 0.085 mmol) was added followed by DMF (220 μL), and the suspension stirred until all solid matter was dissolved. Triethylamine (16 μL, 0.113 mmol, distilled-dry-stored over KOH in the dark) and triphenylphosphine (22.2 mg, 0.085 mmol) were added, and the solution was stirred at 20 °C for 16 h. Product precipitation: The reaction mixture was cooled to 5 °C and a cold solution of NaI (33.8 mg) in dry acetone (2.2 mL) was added at 5 °C. The white precipitate was filtered off and washed with cold acetone. The product was dried under high vacuum for 16 h and stored under argon (crude compound, hygroscopic, yield was not quantified). ^1^H NMR (400 MHz, CD~3~OD): δ 8.38 (s, H-8), 8.19 (s, H-2), 7.88--7.87 (m, 1H, imidazole), 7.28--7.26 (m, 1H, imidazole), 6.99--6.97 (m, 1H, imidiazole), 6.04 (d, 1H, *J* = 6.0 Hz, H-1′), 4.65 (t, 1H, *J* = 5.6 Hz, H-2′), 4.25 (dd, 1H, *J* = 5.2 Hz, *J* = 3.6 Hz, H-3′), 4.18--4.13 (m, 1H, H-4′), 4.06--3.96 (m, 2H, H-5~a,b~^′^). ^31^P NMR (160 MHz, CD~3~OD): δ −9.03 (s, P). ^13^C{^1^H}NMR (100 MHz, CD~3~OD): δ 157.4 (C-6), 153.9 (C-2), 150.9 (C-4), 140.9 (C-8), 140.8 (d, *J* = 5.5 Hz, imidazole), 129.7 (d, *J* = 10.4 Hz, imidazole), 121.3 (d, *J* = 5.7 Hz, imidazole), 120.3 (C-5), 89.2 (C-1′), 85.3 (d, *J* = 8.8 Hz, C-4′), 75.8 (C-2′), 72.19 (C-3′), 66.8 (d, *J* = 5.9 Hz, C-5′). HRMS (ES^--^) calcd for C~13~H~15~N~7~O~6~P, 396.0827 \[M -- H\]^−^; found, 396.0853.

### 1″-β-*O*-Methyl-2″,3″-*O*-isopropylidene adenosine diphosphoriboside (**1**) {#sec4.1.22}

Compound **9** (4.3 mg, 0.009 mmol) and MgCl~2~ (1.8 mg, 0.018 mmol) were dissolved in DMF (1 mL), co-evaporated with dry toluene (2×) and evaporated to dryness. Dry DMF (500 μL) was added to the solid residue and the mixture was stirred at 20 °C until all solids were dissolved (5--10 min). Then, imidazolide **30** (3.5 mg, 0.008 mmol) was added dropwise to the mixture in DMF (400 μL). The mixture was stirred at 20 °C for 3 h, after which conversion to product was 80--90% by HPLC. Solvent was evaporated in vacuo and crude product was dissolved in TEAB buffer (3 mL, 0.1 M) and purified by semi-preparative, reverse-phase HPLC using a gradient of TEAB (0.1 M)--acetonitrile (95:5 → 35:65, v/v). The title compound **1** was obtained as a colorless glass, 1.7 × Et~3~N salt, (2 μmol, 1.57 mg, 24%). ^1^H NMR (500 MHz, D~2~O): δ 8.48 (s, 1H, H-8), 8.20 (s, 1H, H-2), 6.06 (d, 1H, *J* = 5.0 Hz, H-1′), 4.89 (s, 1H, H-1″), 4.70--4.63 (m, 2H, H-2′, 2″), 4.50 (d, 1H, *J* = 5.0 Hz, H-3″), 4.45 (t, 1H, *J* = 5.0 Hz, H-3′), 4.33--4.28 (m, 1H, H-4′), 4.21--4.11 (m, 3H, H-4″, 5~a,b~^′^), 3.82--3.75 (m, 2H, H-5~a,b~^″^), 3.21 (s, 3H, OMe), 3.12 (m, 9H, N**CH**~**2**~CH~3~), 1.31 (s, 3H, CH~3~-*i*Pr), 1.19 (m, 16.5H, NCH~2~**CH**~**3**~, CH~3~-*i*Pr). ^31^P NMR (202 MHz, D~2~O): δ −11.47 (m, pyrophosphate). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 155.1 (C-6), 152.0 (C-2), 149.1 (C-4), 140.0 (C-8), 118.3 (C-5), 112.9 (**C**(CH~3~)~2~), 108.4 (C-1″), 87.0 (C-1′), 84.7 (d, *J* = 10.1 Hz, C-4″), 84.1 (C-3″), 83.9 (d, *J* = 6.3 Hz, C-4′), 80.9 (C-2″), 74.3 (C-2′), 70.3 (C-3′), 65.8 (d, *J* = 3.8 Hz, C-5″), 65.1 (d, *J* = 6.3 Hz, C-5′), 54.7 (OMe), 46.6 (N**CH**~**2**~CH~3~), 25.1 and 23.5 (CH~3~-*i*Pr), 8.2 (NCH~2~**CH**~**3**~). HRMS (ES^--^) calcd for C~19~H~28~N~5~O~14~P~2~, 612.1114 \[M -- H\]^−^; found, 612.1143. UV (H~2~O, pH 7.4) λ~max~ 259 nm (ε 16 900 L/mol·cm). HPLC *t*~R~ = 5.52 min.

### 1″-Deoxyadenosine diphosphoriboside (1″-deoxy-ADPR) (**2**) {#sec4.1.23}

1-Deoxy-[d]{.smallcaps}-ribofuranose-5-phosphate tributylammonium salt **10** (5.8 mg, 0.0145 mmol) and MgCl~2~ (2.8 mg, 0.029 mmol) were dissolved in DMF (1 mL), co-evaporated with dry toluene (2×) and evaporated to dryness. Dry DMF (500 μL) was added to the solid residue and the mixture was stirred at 20 °C until all solids were dissolved (5--10 min). Then, AMP-imidazolide **30** (5.5 mg, 0.013 mmol) was added dropwise to the mixture in DMF (400 μL). The mixture was stirred at 20 °C for 3 h. Solvent was evaporated in vacuo and the crude product was dissolved in TEAB buffer (3 mL, 0.1 M) and purified by semi-preparative, reverse-phase HPLC using a gradient of TEAB (0.1 M)--acetonitrile (95:5 → 35:65, v/v). The title compound **2** was obtained as a colorless glass, 1.7 × Et~3~N salt, (9.6 μmol, 6.86 mg, 66%). ^1^H NMR (500 MHz, D~2~O): δ 8.54 (s, 1H, H-8), 8.26 (s, 1H, H-2), 6.14 (d, 1H, *J* = 5.0 Hz, H-1′), 4.79--4.76 (m, 1H, H-2′, obstructed by H~2~O peak), 4.56--4.52 (m, 1H, H-3′), 4.42--4.38 (m, 1H, H-4′), 4.26--4.21 (m, 3H, H-5~a,b~, H-2″), 4.17--4.14 (m, 1H, H-3″), 4.13--4.07 (m, 1H, H-5″~a~), 4.03--3.92 (m, 3H, H-1″~a~, 4″, 5″~b~), 3.74 (dd, 1H, *J* = 8.5 Hz, *J* = 3.5 Hz, H-1~b~^″^), 3.10 (m, 10H, N**CH**~**2**~CH~3~), 1.18 (m, 15H, NCH~2~**CH**~**3**~). ^31^P NMR (202 MHz, D~2~O): δ −11.35 (m, pyrophosphate). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 155.2 (C-6), 152.3 (C-2), 149.1 (C-4) HMBC, 140.0 (C-8), (C-5) not observed (HMBC), 86.8 (C-1′), 83.9 (d, *J* = 7.6 Hz, C-4′), 80.3 (d, *J* = 7.6 Hz, C-4″), 74.2 (C-2′), 72.2 (C-5~a,b~^″^), 71.6 (C-3″), 70.9 (C-2″), 70.4 (C-3′), 65.5 (d, *J* = 3.8 Hz, C-5~a,b~^″^), 65.2 (d, *J* = 3.8 Hz, C-5′), 46.6 (N**CH**~**2**~CH~3~), 8.2 (NCH~2~**CH**~**3**~). HRMS (ES^--^) calcd for C~15~H~22~N~5~O~13~P~2~, 542.0695 \[M -- H\]^−^; found, 542.0716. UV (H~2~O, pH 7.4) λ~max~ 259 nm (ε 15 958 L/mol·cm). HPLC *t*~R~ = 2.93 min.

### 1″-α/β-2″-Deoxyadenosine diphosphoriboside (2″-deoxy-ADPR) (**3**) {#sec4.1.24}

2-Deoxyribose-5-phosphate tributylammonium salt **11** (8 mg, 0.029 mmol) and MgCl~2~ (5.6 mg, 0.058 mmol) were dissolved in DMF (1.5 mL), co-evaporated with dry toluene (2×), and evaporated to dryness. Dry DMF (500 μL) was added to the solid residue and the mixture was stirred at 20 °C until all solids dissolved (5--10 min). Then, AMP-imidazolide **30** (9 mg, 0.0215 mmol) was added dropwise to the mixture in DMF (700 μL). The mixture was stirred at 20 °C for 16 h (HPLC showed a complex reaction mixture comprising 3--4 products, including AMP and AMP dinucleotide). The solvent was evaporated in vacuo and the crude product was dissolved in TEAB buffer (3 mL, 0.1 M) and purified by semi-preparative, reverse-phase HPLC using a gradient of TEAB (0.1 M)--acetonitrile (95:5 → 35:65, v/v). The title compound was obtained as a colorless glass as a mixture of anomers β/α 0.45:0.55, 1.7 × Et~3~N salt, (1.72 μmol, 1.23 mg, 8%). ^1^H NMR (500 MHz, D~2~O): δ 8.43 (s, 1H, H-8), 8.19 (s, 1H, H-2), 6.06 (d, 1H, *J* = 10.0 Hz, H-1′), 5.49--5.46 (m, 0.45H, H-1″β), 5.42--5.39 (m, 0.55H, H-1″α), 4.70--4.68 (m, 1H, H-2′, obstructed by H~2~O peak), 4.47--4.43 (m, 1H, H-3′), 4.37--4.33 (m, 0.45H, H-3″β), 4.33--4.29 (m, 1H, H-4′), 4.23--4.19 (m, 0.55H, H-3″α), 4.16--4.10 (m, 2.45H, H-4″α and H-5′), 3.93--3.89 (m, 1.45H, H-4″β and H-5″β), 3.87--3.83 (m, 1H, H-5″α), 3.12 (q, 10H, *J* = 7.5 Hz, N**CH**~**2**~CH~3~), 2.30--2.23 (m, 0.55H, H-2~a~^″^-α), 2.06--2.01 (m, 0.9H, H-2~a,b~^″^-β), 1.77--1.70 (m, 0.55H, H-2~b~^″^-α), 1.19 (t, 15H, *J* = 7.5 Hz, NCH~2~**CH**~**3**~). ^31^P NMR (202 MHz, D~2~O): δ −11.34 (m, pyrophosphate). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 155.7 (C-6), 152.9 (C-2), 149.1 (C-4), 139.8 (C-8), 118.6 (C-5), 98.4 (C-1″β), 98.1 (C-1″α), 86.7 (C-1′, 84.0 and 83.9 (m, C-4′, 4″α, 4″β), 74.2 (C-2′), 71.4 (C-3″β), 71.0 (C-3″α), 70.4 (C-3′), 66.4 (d, *J* = 3.8 Hz, C-5″β), 65.6 (d, *J* = 2.5 Hz, C-5″α), 65.2 (d, *J* = 3.8 Hz, C-5′), 46.6 (N**CH**~2~CH~3~), 40.6 (C-2″α, β), 8.3 (NCH~2~**CH**~**3**~). HRMS (ES^--^) calcd for C~15~H~22~N~5~O~13~P~2~, 542.0695 \[M -- H\]^−^; found 542.0690; (ES^+^) calcd for C~15~H~22~N~5~NaO~13~P~2~, 565.0587 \[M + Na\]^+^; found, 565.0579. HPLC *t*~R~ = 3.10 min.

### 1″-α/β-3″-Deoxyadenosine diphosphoriboside (3″-deoxy-ADPR) (**4**) {#sec4.1.25}

3-Deoxy-[d]{.smallcaps}-ribofuranose-5-phosphate tributylammonium salt **12** (10 mg, 0.025 mmol) and MgCl~2~ (4.9 mg, 0.05 mmol) were dissolved in DMF (1 mL), co-evaporated with dry toluene (2×), and evaporated to dryness. Dry DMF (600 μL) was added to the solid residue, and the mixture was stirred at 20 °C until all solids were dissolved (5--10 min). Then, AMP-imidazolide **30** (9.4 mg, 0.023 mmol) was added dropwise to the mixture in DMF (400 μL). The mixture was stirred at 20 °C for 16 h. Solvent was evaporated in vacuo, and the crude product was dissolved in TEAB buffer (3 mL, 0.1 M) and purified by semi-preparative, reverse-phase HPLC using a gradient of TEAB (0.1 M)--acetonitrile (95:5 → 35:65, v/v). The title compound **4** was obtained as a colorless glass, 1.7 × Et~3~N salt, (3.88 μmol, 2.8 mg, 17%). ^1^H NMR (500 MHz, D~2~O, water suppression exp.): δ 8.37 (s, 1H, H-8), 8.11 (s, 1H, H-2), 5.98 (d, 1H, *J* = 6.0 Hz, H-1′), 5.10 (d, 0.3H, *J* = 4.0 Hz, H-1″α), 5.06 (s, 0.7H, H-1″β), 4.63 (t, 1H, *J* = 5.5 Hz, H-2′), 4.40--4.37 (m, 1H, H-3′), 4.34--4.27 (m, 1H, H-4″α, β), 4.26--4.22 (m, 1H, H-4′), 4.12--4.04 (m, 2.3H, H-2″α, 5~a,b~^′^), 4.04--4.01 (m, 0.7H, H-2″β), 3.91--3.85 (m, 0.7H, H-5″β~a~), 3.81--3.71 (m, 1H, H-5″α~a~, β~b~), 3.69--3.63 (m, 0.3H, H-5″α~b~), 3.04 (q, 10H, *J* = 7.5 Hz, N**CH**~**2**~), 1.90 (ddd, 0.3H, *J* = 13.0 Hz, *J* = 7.5 Hz, *J* = 2.0 Hz, H-3″α~a~), 1.84--1.78 (m, 1.7H, H-3″α~b~, β~a,b~), 1.12 (t, 15H, *J* = 7.5 Hz, NCH~2~**CH**~**3**~). ^31^P NMR (202 MHz, D~2~O): δ −11.17 (m, α-pyrophosphate), −11.46 (m, β-pyrophosphate). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 155.1 (C-6), 152.1 (C-2), 149.0 (C-4), 139.9 (C-8), 118.5 (C-5), 102.0 (C-1″β), 96.5 (C-1″α), 86.7 (C-1′), 83.9 (d, *J* = 8.7 Hz, C-4′), 78.2 (d, *J* = 8.4 Hz, C-4″β), 75.5 (d, *J* = 8.4 Hz, C-4″α), 75.3 (C-2″β), 74.2 (C-2′), 70.3 (C-3′), 70.3 (C-2″α), 68.8 (d, *J* = 5.2 Hz, C-5″β), 67.8 (d, *J* = 4.8 Hz, C-5″α), 65.1 (d, *J* = 5.0 Hz, C-5′), 46.5 (N**CH**~**2**~), 32.3 (C-3″β), 31.5 (C-3″α), 8.1 (NCH~2~**CH**~**3**~). HRMS (ES^--^) calcd for C~15~H~22~N~5~O~13~P~2~, 542.0695 \[M -- H\]^−^; 542.0716. HPLC *t*~R~ = 2.87 min.

### 2′-Deoxy AMP Imidazolide: 2′-Deoxy-adenosine-5′-phosphoryl Imidazolide (**31**) {#sec4.1.26}

2′-Deoxy-AMP was treated in the same way as AMP to generate the mono Bu~3~N salt (**29**).

2′-Deoxy-AMP mono-tributylammonium salt **29** (145 mg, 0.28 mmol) and imidazole (191 mg, 2.8 mmol) were put into the flask and co-evaporated with EtOH (2×) and with toluene (2×). Aldrithiol (186 mg, 0.84 mmol) was added to the flask followed by dry DMF (1.5 mL) and stirred until all solid matter was dissolved. Triethylamine (156 μL, 1.13 mmol, distilled-dry-stored over KOH in the dark) and triphenylphosphine (221 mg, 0.85 mmol) were added to the mixture, and the mixture was stirred at 20 °C for 16 h. The reaction mixture was cooled to 5 °C, and a cold solution of NaI (337 mg, 2.25 mmol) in dry acetone (15 mL) was added at 5 °C. The white precipitate was filtered off and washed with cold acetone. The product was dried under high vacuum and stored under argon (crude compound, hygroscopic, yield was not quantified). ^1^H NMR (400 MHz, CD~3~OD): δ 8.36 (s, H-8), 8.18 (s, H-2), 7.87--7.86 (m, 1H, imidazole), 7.26--7.24 (m, 1H, imidazole), 6.98--6.96 (m, 1H, imidazole), 6.44 (dd, 1H, *J* = 7.6 Hz, *J* = 1.2 Hz, H-1′), 4.49 (q, 1H, *J* = 2.8 Hz, H-3′), 4.08--4.04 (m, 1H, H-4′), 3.99--3.95 (m, 2H, H-5′), 2.75 (ddd, 1H, *J* = 13.6 Hz, *J* = 7.6 Hz, *J* = 1.6 Hz, H-2~a~^′^), 2.42 (dq, 1H, *J* = 13.6 Hz, *J* = 2.8 Hz, H-2~b~^′^). ^31^P NMR (160 MHz, CD~3~OD): δ −9.00 (s, P). ^13^C{^1^H}NMR (100 MHz, CD~3~OD): δ 157.3 (C-6), 153.8 (C-2), 150.5 (C-4), 140.9 (C-8), 140.7 (d, *J* = 5.5 Hz, imidazole), 129.6 (d, *J* = 10.5 Hz, imidazole), 121.3 (d, *J* = 5.7 Hz, imidazole), 120.3 (C-5), 87.5 (d, *J* = 8.7 Hz, C-4′), 85.5 (C-1′), 72.9 (C-3′), 67.0 (d, *J* = 5.9 Hz, C-5′), 41.2 (C-2′). HRMS (ES^--^) calcd for C~13~H~15~N~7~O~5~P, 380.0878 \[M -- H\]^−^; found, 380.0883.

### 1″,2′-Dideoxyadenosine diphosphoriboside (1″,2′-deoxy ADPR) (**5**) {#sec4.1.27}

1-Deoxy-[d]{.smallcaps}-ribofuranose-5-phosphate tributylammonium salt **10** (12 mg, 0.03 mmol) and MgCl~2~ (5.9 mg, 0.06 mmol) were dissolved in DMF (1 mL), co-evaporated with dry toluene (2×), and evaporated to dryness. Dry DMF (600 μL) was added to the solid residue and the suspension was stirred at 20 °C until all solids were dissolved (5--10 min). Then, 2′-dAMP-imidazolide **31** (10.8 mg, 0.027 mmol) was added dropwise in DMF (400 μL). The mixture was stirred at 20 °C for 3 h. HPLC showed consumption of all starting material. The solvent was evaporated in vacuo, and the crude product was dissolved in TEAB buffer (10 mL, 0.1 M) and purified by semi-preparative, reverse-phase HPLC using a gradient of TEAB (0.1 M)--acetonitrile (95/5 → 35/65, v/v). The title compound **5** was obtained as a colorless amorphous solid (11.3 μmol, 8.02 mg, 42%, 1.8 × Et~3~N salt). ^1^H NMR (500 MHz, D~2~O): δ 8.47 (s, 1H, H-8), 8.23 (s, 1H, H-2), 6.50 (t, 1H, *J* = 5.0 Hz, H-1′), 4.79--4.74 (m, 1H, H-3′, obstructed by water peak), 4.31--4.28 (m, 1H, H-4′), 4.25--4.21 (m, 1H, H-2″), 4.19--4.11 (m, 3H, H-3″, 5~a,b~^′^), 4.10--4.05 (m, 1H, H-5~a~^″^), 4.02--3.92 (m, 3H, H-1~a~^″^, 4″, 5~b~^″^), 3.74 (dd, 1H, *J* = 10.0 Hz, *J* = 2.5 Hz, H-1~b~^″^), 3.19 (q, 10H, *J* = 7.5 Hz, N**CH**~**2**~CH~3~), 2.83 (quint, 1H, *J* = 7.0 Hz, H-2~a~^′^), 2.59 (dq, 1H, *J* = 14.0 Hz, *J* = 3.0 Hz, H-2~b~^′^), 1.27 (t, 15H, *J* = 7.0 Hz, NCH~2~**CH**~**3**~). ^31^P NMR (202 MHz, D~2~O): δ −11.33 (m, pyrophosphate). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 155.5 (C-6), 152.7 (C-2), 148.7 (C-4), 139.9 (C-8), 118.6 (C-5), 85.7 (d, *J* = 8.6 Hz, C-4′), 83.6 (C-1′), 80.3 (d, *J* = 8.4 Hz, C-4″), 72.2 (C-1″), 71.5 (C-3″), 71.2 (C-3′), 70.9 (C-2″), 65.5 and 65.4 (2 × d, *J* = 5.3 Hz, *J* = 4.7 Hz, C-5′, 5″), 64.6 (N**CH**~**2**~CH~3~), 39.0 (C-2′), 8.2 (NCH~2~**CH**~**3**~). HRMS (ES^--^) calcd for C~15~H~22~N~5~O~12~P~2~, 526.0746 \[M -- H\]^−^; found, 526.0768. HPLC *t*~R~ = 3.7 min.

### 1″-α/β-3″,2′-Dideoxyadenosine diphosphoriboside (3″,2′-dideoxy-ADPR) (**6**) {#sec4.1.28}

3-Deoxy-[d]{.smallcaps}-ribofuranose-5-phosphate tributylammonium salt **12** (12 mg, 0.03 mmol) and MgCl~2~ (5.9 mg, 0.06 mmol) were dissolved in DMF (1 mL), co-evaporated with dry toluene (2×), and evaporated to dryness. Dry DMF (600 μL) was added to the solid residue, and the mixture was stirred at 20 °C until all solids were dissolved (5--10 min). Then, 2′-deoxy-AMP-imidazolide **31** (10.8 mg, 0.027 mmol) was added dropwise in DMF (400 μL). The mixture was stirred at 20 °C for 16 h. HPLC showed consumption of all starting material. The solvent was evaporated in vacuo and the crude product was dissolved in TEAB buffer (10 mL, 0.1 M) and purified by semi-preparative, reverse-phase HPLC using a gradient of TEAB (0.1 M)--acetonitrile (95/5 → 35/65, v/v). The title compound **6** was obtained as a colorless amorphous solid (7.5 μmol, 5.32 mg, 27%, 1.8 × Et~3~N salt). ^1^H NMR (500 MHz, D~2~O): δ 8.48 (s, 1H, H-8), 8.24 (s, 1H, H-2), 6.51 (t, 1H, *J* = 7.0 Hz, H-1′), 5.26 (d, 0.3H, *J* = 4.0 Hz, H-1″α), 5.21 (s, 0.7H, H-1″β), 4.78--4.75 (m, 1H, H-3′, obstructed by water signal), 4.49--4.39 (m, 1H, H-4″α, β), 4.31--4.23 (m, 1.3H, H-2″α, 4′), 4.20--4.11 (m, 2.7H, H-2″β, 5~a,b~^′^), 4.05--3.98 (m, 0.7H, H-5″β~a~), 3.94--3.84 (m, 1H, H-5″α~a~, β~b~), 3.82--3.76 (m, 0.3H, H-5″α~b~), 3.19 (q, 11H, *J* = 7.5 Hz, N**CH**~**2**~), 2.84 (ddd, 1H, *J* = 7.5 Hz, *J* = 6.5 Hz, *J* = 1.0 Hz, H-2~a~^′^), 2.63--2.57 (m, 1H, H-2~b~^′^), 2.10--2.01 (m, 0.3H, H-3″α~a~), 2.00--1.92 (m, 1.7H, H-3″α~b~, β~a,b~), 1.27 (t, 16.5H, *J* = 7.5 Hz, NCH~2~**CH**~**3**~). ^31^P NMR (202 MHz, D~2~O): δ −11.12 (m, α-pyrophosphate), −11.38 (m, β-pyrophosphate). ^13^C{^1^H}NMR (126 MHz, D~2~O): δ 155.6 (C-6), 152.7 (C-2), 148.7 (C-4), 139.9 (C-8), 118.6 (C-5), 102.1 (C-1″β), 97.6 (C-1″α), 85.8 (d, *J* = 8.8 Hz, C-4′), 83.6 (C-1′), 78.3 (d, *J* = 8.2 Hz, C-4″β), 75.5 (d, *J* = 8.4, C-4″α), 75.4 (C-2″β), 71.3 (C-3′), 70.4 (C-2″α), 68.8 (d, *J* = 5.4 Hz, C-5″β), 67.9 (d, *J* = 5.5 Hz, C-5″α), 65.4 (d, *J* = 4.9 Hz, C-5′), 46.6 (N**CH**~**2**~), 39.0 (C-2′), 32.4 (C-3′β), 31.7 (C-3′α), 8.2 (NCH~2~**CH**~**3**~). HRMS (ES^--^) calcd for C~15~H~22~N~5~O~12~P~2~, 526.0746 \[M -- H\]^−^; 526.0761. HPLC *t*~R~ = 3.68 min.

Pharmacology {#sec4.2}
------------

### Materials {#sec4.2.1}

ADPR was obtained from Sigma-Aldrich.

### Cell Culture {#sec4.2.2}

HEK293 cells were kept at 37 °C and 5% CO~2~ in complete medium (DMEM with 4.5 g/L glucose, Glutamax-I, 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin) at 37 °C. For the maintenance of HEK293 clones with stable expression of TRPM2 400 μg/mL G418 sulfate was added to the medium.

### Transfection and Generation of Cell Lines {#sec4.2.3}

Generation of the clonal HEK293 cell line with stable expression of human TRPM2 has been described previously.^[@ref16]^ In brief, HEK293 were transfected with an expression vector encoding the full-length of human TRPM2 and EGFP (pIRES2-EGFP-TRPM2). Cells that successfully integrated the expression vector were then enriched by selection with 400 μg/mL G418 sulfate (Biochrom). Clonal cell lines were established from these cells by limiting dilution. Expression of TRPM2 was confirmed by Ca^2+^ measurement and whole cell patch clamp.

### Patch-Clamp Measurements {#sec4.2.4}

The day before the experiments, cells from a clonal HEK293 cell line with stable expression of human TRPM2 were seeded to 35 mm tissue culture dishes at a low density. For the whole cell patch-clamp experiments, the culture medium was replaced by a bath solution containing 1 mM CaCl~2~, 140 mM NMDG, 5 mM KCl, 3.3 mM MgCl~2~, 1 mM CaCl~2~, 5 mM [d]{.smallcaps}-glucose, and 10 mM HEPES, pH 7.4. Patch pipettes were pulled from borosilicate glass capillaries with an outer diameter of 1.5 mm and an inner diameter of 1.05 mm using a Sutter P-97 and filled with a pipette solution containing 120 mM KCl, 8 mM NaCl, 1 mM MgCl~2~, 10 mM HEPES, 10 mM EGTA, and 5.6 mM CaCl~2~ (resulting in 200 nM free \[Ca^2+^\] as calculated by CaBuf software (G. Droogmans, formerly available from <ftp://ftp.cc.kuleuven.ac.be/pub/droogmans/cabuf.zip>). These pipettes had a resistance between 1.5 and 3.5 MΩ. Data were recorded using an EPC-10 amplifier and PatchMaster software (HEKA Elektronik, Germany). Fast and slow capacity transients were compensated, series resistance was compensated by 70%. After establishing whole cell configuration, cells were held at −50 mV and channel activation was followed by applying voltage ramps from −85 to +20 mV over 140 ms every 5 s for a total of 450 s. For further analysis, the maximum outward current at +15 mV during the course of the recording was taken as a measure of channel activity. To test for agonist activity, ADPR analogues were included in the pipette solution at 100 μM. To test for antagonist activity, the pipette solution contained 100 μM ADPR and 900 μM of the ADPR analogue under test. All experiments were performed at room temperature.

### Statistical analysis {#sec4.2.5}

The data from patch-clamp experiments were analyzed using GraphPad Prism (version 7.04, GraphPad Software Inc.) Because the distribution of currents is skewed toward higher values, data were log-transformed. Log-transformed data were tested for significant differences using one-way-Anova followed by post hoc testing against the respective control (buffer for agonist experiments, ADPR for antagonist experiments) using Bonferroni correction for multiple testing (α = 0.05). In the charts, the horizontal bar indicates the mean of the log-transformed data.
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